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Association of COX-2 Promoter Polymorphism 
with Gastroesophageal Reflux Disease (GERD) 
and Gastrointestinal Cancers from Iran: An 
Application for the Design of Early Detection 
 of Cancer and Providing Prognostic 
 Information to Patients in a Clinical Setting 
Firouzeh Biramijamal 
National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, 
Iran 
1. Introduction 
Cyclooxygenase (COX) is a key enzyme responsible for developing several inflammatory 
diseases that may lead to cancer. The COX is an enzyme (EC 1.14.99.1) that it alters 
formation of prostanoids, including prostaglandins, prostacyclin and thromboxane. This 
enzyme converts arachidonic acid to prostaglandin H2 (PGH2) which it precursor of the 
prostanoids. The COX enzyme has two active sites, including heme site and cyclooxygenase 
site. The heme site has proxidase activity that alters the reduction of PGG2 (hydroperoxy 
endoperoxide prostaglandin G2) to PGH2, and, cyclooxygenase site converts arachidonic 
acid into PGG2. It is described three COX isoenzymes, including COX-1, COX-2 and COX-3 
(splice variant of COX-1). COX-1 is a constitutive enzyme and, it is expressed in most 
mammalian cells. Conversely, COX-2 is not expressed in most normal mammalian tissues, 
so, it is an inducible enzyme and it is increased in activated macrophages and during 
inflammation. Inflammation has central role for tumor progression. Presence of 
inflammatory cells can lead DNA-damage-promoting agents. Now, it is clear the 
relationship between inflammation and cancer. Macrophage can be produced Transforming 
growth factor (TGF-α), consequential, permeability of the blood vessel and endothelium is 
increased in the presence of inflammation and in response to prostaglandins which is 
produced by COX-2 enzyme. Therefore, in this microenvironment with inflammatory cells, 
the extracellular matrix degradation can be occurred. Disruption of communication between 
the epithelium and stroma can promote cancer. Induction of Vascular endothelial growth 
factor (VEGF) and angiogenesis are observed after growing tumor cells, and presence of 
hypoxia. So, tumor cells can be received nutrients for more growth, figure 1. 
COX-2 gene expression is enhanced in chronic inflammation. During prolonged 
inflammation, known as chronic inflammation, macrophages are produced TGF-α which it 
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Fig. 1. Enhanced expression of COX-2 enzyme promotes tumor growth and cancer 
progression during prolonged (chronic) inflammation. 
cells and inflammatory signals. Hypoxia is pushed the cells to produce Hypoxia-Inducible 
factor (HIF) which stimulates the release of VEGF. So, VEGF binds to VEGF receptors on 
endothelial cells, and leading angiogenesis. Also, matrix metalloproteinases (MMPs) 
upregulates in tumor cells microenvironment to degrade extracellular matrix proteins and 
tumor growth progression.  
It is found that the COX-2 enzyme  up-regulates in various carcinomas and it is described 
the role of COX-2 at an early stage in tumorigenesis. The COX-2 enzyme has been shown as 
an important mediator of proliferation through the increased formation of metabolites such 
as prostaglandin E2. Also, it can be increased the formation of heptanone-etheno (Hε)-DNA 
adducts which are highly mutagenic in mammalian cell lines, and accelerate the somatic 
mutations which are detected in tumorigenesis. It is observed that somatic mutations could 
be arised about 80% of various cancers. 
Enhanced expression of COX-2 has been reported in many types of cancer including breast, 
colon, lung, pancreas, prostate, esophageal during prolonged inflammation, chronic 
inflammation. So, COX-2 is involved in mechanisms of carcinogenesis. COX-2 expression 
and activity is induced by inflammatory signals and carcinogens. COX-2 overexpression is 
associated with cancer development. The COX-2 gene is located at 1q25.2-q25.3. 
The promoter region of the COX-2 gene consists of various transcriptional regulatory 
elements including stimulatory protein 1 (Sp1) binding site. The COX-2 promoter variation 
alters putatively functional transcription factor-binding sites. A variant at position -765 
G→C in promoter of COX-2 gene is involved in modification of COX-2 gene expression. 
Additionally, COX-2 -765G→C genetic variation is linked to change the level of gene 
expression and serum concentrations of C-reactive protein and prostaglandin E2, and, 
inflammatory response is different among individuals with varient alleles, figure 2.  
We describe in this investigation the role of COX-2 genetic variation at -765 of promoter 
region on the risk of gastrointestinal cancers, and also, gastroesophageal reflux (GERD) as  
a risk factor for developing Barrett’s esophagus and then esophageal adenocarcinoma.  
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Fig. 2. Inflammatory response is different among individuals with varient alleles for COX-2 
gene. The G→C substitution at -765 promoter of COX-2 gene can be changed gene 
expression and level of serun concentration of PGE2.  
Colorectal and esophageal cancers are frequent tumor types in gastrointestinal tract 
cancers. The COX-2 enzyme is known to be elevated in chronically inflamed tissues and 
gastrointestinal tumors. The COX-2 gene expression is dependent of interaction of nuclear 
proteins with the COX-2 promoter region. The promoter region of the COX-2 gene plays 
an important role in gene transcription. The single nucleotide polymorphisms in the COX-
2 promoter can modified the binding of nuclear protein and consequentially, the level of 
gene expression and it can be changed susceptibility to cancer including gastrointestinal 
cancer.  
It is described that reflux esophagitis can be changed to Barrett’s esophagus (BE), and 
then, the risk of esophageal adenocarcinoma can be elevated 30- to 125- fold. The gastric 
acid reflux is the cause of esophageal damage in GERD. One of the most effective risk 
factors for inducing Barrett’s esophagus (BE) is Gastroesophageal reflux disease. 
Gastroesophageal reflux disease (GERD) has been reported as a common disease 
worldwide. During reflux in the GERD, induction of the esophageal mucosal damage can 
be occurred due to inflammation. Also, chronic inflammation can be caused of 
progressing chronic esophagitis and premalignant Barrett’s esophagus. The over 
expression of COX-2 gene is during chronic inflammation. It might be developed BE and 
adenocarcinoma (ADC) of the esophagus.  
Barrett’s esophagus epithelium is a premalignant condition prior to esophageal 
adenocarcinoma (ADC). The level of cyclooxygenase-2 enzyme is high in BE epithelium. It is 
shown that COX-2 gene expression is elevated 5-fold in Barrett’s esophagus and 16-fold in 
esophageal adenocarcinoma compared to normal esophageal from healthy individuals. 
Additionally, it is seemed that COX-2 protein expression in the esophagus is independent of 
the degree of inflammation. Also, it is suggested that over expression of COX-2 can be used 
as a biomarker for detection of development of esophageal adenocarcinoma related to 
Barrett’s metaplasia. The over expression of COX-2 is associated with esophageal 
carcinogenesis, and, the condition of tumor aggressive is dependent on the level of COX-2 
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It is reported that the individuals with -765C allele of the COX-2 gene are susceptible to 
esophageal cancer (both SCC and ADC lesions). 
In addition, chronic inflammation can be caused of esophageal squamous cell carcinoma 
(ESCC) in Iran against western countries. In previous studies, it is reported that 
overexpression of COX-2 is approximately 70% among esophageal squamous cell carcinoma 
(ESCC) from Iranian patients and it is associated with p53 mutations. That investigation 
demonstrated the role of inflammation in carcinogenesis of ESCC in Iran as opposed to 
western countries. Comparing with esophageal cancer especially ESCC, the incidence of 
colorectal cancer (CRC) is relatively low in Iran.  
In this chapter, it is described the association of COX-2 promoter polymorphism with 
gastroesophageal reflux disease (GERD) and gastrointestinal cancers from Iran. It might be 
an application for the design of early detection of cancer and providing prognostic 
information to patients in a clinical setting. In the next pages, it can be find some results for 
this aim.  
2. Materials and methods 
For this purpose, blood and archival cancerous human tissues from ESCC and CRC 
samples, also, esophageal tissue samples from GERD patients were collected. This study 
included 43 formalin-xed, parafn-embedded (FFPE) tissues from patients diagnosed with 
ESCC who had undergone curative surgical resection at Imam Khomeini hospital, 17 
colorectal cancer tissues from patients diagnosed with adenocarcinoma who had undergone 
curative surgical resection at Tehran hospital. Then blood samples from eighty-two patients 
with at least one of three important symptoms of GERD (heart burn, acid regurgitation, or 
dysphagia) and erosive reflux esophagitis as diagnosed by endoscopy at the Endoscopy 
Ward of Fayazbakhsh Hospital (Tehran, Iran) and from 103 healthy indivituals were 
selected.  
None of the GERD patients had taken proton pump inhibitors and Nonsteroidal anti-
inflammatory drugs (NSAIDs) during last 4 weeks before beginning of the study. All cases 
underwent treatment with omeprazole as a proton pump inhibitors (PPIs) at 20 mg twice 
daily for 4 weeks. At the end of treatment, second endoscopy was performed for all patients 
and second biopsy was obtained from the previous site. 
The tissue samples from cancer patients were examined by a pathologist according to the 
pathological features of the tumors. Informed consent was obtained from patients and 
healthy individuals followed by completion of a structured questionnaire. Also, this study 
was approved by the National Institute for Genetic Engineering and Biotechnology. 
Hospital records were used to verify age, permanent residence, and ethnicity of 
individuals.  
Genomic DNA was obtained from FFPE tissues in cases and from whole blood of patients and 
healthy individuals by the QIAGEN Flexigen kit or QIAamp DNA minikit (Qiagen,  
Valencia, CA). The extracted DNA was then kept in a -20ºC freezer until further  
use. The COX-2 -765G → C genotyping was performed by PCR, and a fragment of  
228 bp was amplied from DNA isolated from FFPE tissues and blood using  
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the primers COX F: 5′-CATTAACTATTTACAGGGTAACTGCTT-3′ and COX R: 5′-
TGCAGCACATACATACATAGCTTTT-3′. PCR was performed in a 25-µl volume containing 
100 ng DNA template, 50 pmol each primer, 10 mM each dNTP, 2.5 µl Q solution buffer, and 
2.5 µl coral buffer, 1 U/ µl Taq DNA polymerase (HotStarTaq Plus PCR kit from Qiagen). 
Initial denaturation for 10 min at 94ºC was followed by 35 three-step cycles at 94ºC for 30 s, at 
56ºC for 30 s, and at 72ºC for 30 s. The PCR products were subsequently digested with 10 U 
SsiI (Fermentas, Lithuania) for 3 h at 37ºC and separated on a 3% agarose gel. If the CC 
genotype does not cut the PCR product, then there is a 228-bp fragment. If there is a GC, there 
is a cut site, and theoretically it should yield a 228 bp + 168 and 60 bp fragment. The GG 
genotype should give only a 168-bp and 60-bp fragment, figures 3 & 4. To conrm the result of 
PCR-RFLP, selected PCR products were subjected to DNA sequence analysis, figure 5.  
 
                         








Fig. 3. A PCR assay to detect genetic polymorphism at the COX-2 promoter region. A 228 bp 
region of genomic DNA flanking -765 of promoter was amplified using primers which were 
described in the text. (A) The PCR products run on 2% agarose gel for cases numbers 3.3, 
664.8, and 578.2 which were compared with negative control (NA), PCR reaction without 
using genomic DNA to control analysis and possibility of contamination, and a Molecular 
Weight marker (MW). (B) Detection of peak of PCR product with light cycler instrument to 
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Fig. 4. Running digested PCR product with SsiI restriction enzyme on 3% agarose gel to 
detect of COX-2 polymorphism at -765 of the promoter region. Lane 1, sample with 
condition of homozygous genotype (G/G); Lane 2, sample with condition of heterozygous 
genotype (G/C); Lane 3, sample with condition of homozygous genotype (C/C); Lane 4, 
negative control (NA) to control the condition of digestion procedure using a reaction 





Fig. 5. Electropherogram of DNA sequencing (5′→3′) showing a single base substitution 
(G→C) polymorphism at nucleotide -765 of promoter region. (A) homozygous wild 
genotype (G/G). (B) heterozygous genotype (G/C). (C) homozygous genotype (C/C).  
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Of the 82 esophagitis tissue samples examined in this study for the COX-2 genetic 
polymorphism, frozen samples of 19 patients were available for evaluation of mRNA 
expression for COX-2 gene. The tissues were taken from GERD patients by endoscopic 
biopsy, and then, the samples immersed in RNA later (QIAGEN, Valencia, CA) for RNA 
preservation, where the tissue-containing tubes were kept in a -70°C freezer for later use. 
RNA extraction was performed by the QIAGEN RNeasy Kit, and the RNA samples were 
kept at -70°C. 
For analysis of COX-2 gene expression we used real-time PCR method by Roche Lightcycler 
apparatus. Real-time PCR were carried out in a 25-µl. Reaction volume in Roche capillaries. 
The reaction mixture contains 0.5 µl TaKaRa Ex.taq and 12.5 µl TaKaRa one step Master mix, 
and 0.5 µl TaKaRa RT primers and 7.5 µl TaKaRa RNase free distilled water and forward and 
reverse COX-2 RT primers, each one 10 pmoL, and 2 μL tissue total RNA containing 250 ng 
total tissue mRNA. For internal control, we used β-actin for normalizing the expression  
values between all samples and obtaining comparative expression values relative to β-actin.  
Primers for the reactions were COX-2 forward: 5′-CCTTCCTCCTGTGCCTGATG -3′ and  
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standard sample for COX-2, one standard sample for β-actin, and also a negative control for 
COX-2 and a negative control for β-actin. COX-2 to β-actin comparative values were obtained 
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and healthy controls. COX-2 real-time program consisted of three phases; a reverse 
transcription phase for 5-10 min at 42°C, then an amplification-quantification phase of 50 
cycles of one denaturation step at 95°C for 5 s and one elongation step at 60°C for 35 s, and a 
final phase of melting by increasing the temperature from 65°C to 100°C in 15 s. 
The P values of COX-2 genotype comparisons between cases and control groups were 
considered statistically significant and were below 0.05. This measurement was made by  
2x and Fisher’s exact test. SPSS version 16 was used for all statistical analyses.  
For comparison of COX-2 gene expression means, it is used the Student t-test, and ANOVA 
was applied for comparison of multiple groups in regard to their quantitative expression 
levels. 
3. Results 
Detection of COX-2 genotype for Cases (ESCC, CRC, and GERD/Control) 
We investigated the role of COX-2 -765G→C polymorphism in a case–control study to nd 
the distribution of allele frequencies. This polymorphism is known to modulate the 
transcriptional activity and expression of the gene. The study group of 142 patients included 
43 ESCC, 17 colorectal cancers and 82 GERD genotyped for COX-2 polymorphism data. We 
assayed DNA from these samples for the frequency of allelic polymorphism at position -
765G→C in the COX-2 gene. In healthy individuals, the distribution of genotypes ts the 










Fig. 4. Running digested PCR product with SsiI restriction enzyme on 3% agarose gel to 
detect of COX-2 polymorphism at -765 of the promoter region. Lane 1, sample with 
condition of homozygous genotype (G/G); Lane 2, sample with condition of heterozygous 
genotype (G/C); Lane 3, sample with condition of homozygous genotype (C/C); Lane 4, 
negative control (NA) to control the condition of digestion procedure using a reaction 





Fig. 5. Electropherogram of DNA sequencing (5′→3′) showing a single base substitution 
(G→C) polymorphism at nucleotide -765 of promoter region. (A) homozygous wild 
genotype (G/G). (B) heterozygous genotype (G/C). (C) homozygous genotype (C/C).  
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groups of cancer patients (P=0.05), but the distribution of the CC genotype was different in 
the two groups (P = 0.001): 23.25% (10 of 43 patients) for ESCC and 5.8% (1 of 17 patients) 
for colorectal cancers. Our results showed that the frequency of the C allele (GC + CC 
genotypes of the COX-2 gene at position -765G→C among the cancer patients and GERD 
patients are high compared with controls. The variation of the allele frequency among 













































Fig. 7. Frequency of various genotypes of COX-2 gene among CRC patients versus healthy 
individuals.  
Association of COX-2 Promoter Polymorphism with Gastroesophageal Reflux Disease (GERD) 






















Fig. 8. Frequency of various genotypes of COX-2 gene among GERD patients versus healthy 
individuals.  
COX-2 gene expression 
Nineteen patients were enrolled in this study. We found that eight cases (42.1%) were -
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Fig. 9. Distribution of nucleotide variation at -765 promoter of COX-2 gene and its effect on 
level of COX-2 over expression. It is showed in this study that COX-2 overexpression is 
remained high among GERD patients after treatment with Omeprazole. It is assumed that C 
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COX-2 mRNA expression was detectable by quantitative real-time RT-PCR in all of 38 tissue 
samples (were obtained from 19 patients in pre and post- treatment statuses). The over 
expression of COX-2 gene remained high after treatment with Omeprazole in the most of 
patients with GERD. The differences was identical among the two groups of investigated 
samples (P=0.07). 
4. Discussion 
The level of the COX-2 enzyme is elevated during inammation, reflux esophagitis and in 
many types of cancers, including ESCC and colorectal cancer In addition, it is reported that 
COX-2 promoter polymorphisms can modulate the expression of the COX-2 gene. 
Our results in the present study showed that the frequency of the C allele (GC + CC 
genotypes of the COX-2 gene at position -765G→C) among the patients is high compared 
with controls. This investigation could clarify the importance of the COX-2 variants in reflux 
esophagitis and gastrointestinal carcinogenesis in Iran. Our results show that C carriers are 
at higher risk for GERD, ESCC and colorectal cancers. In this study, it is found that the COX-
2 over expression was remained after treatment period with Omeperazole in GERD patients 
with C allele at site of -765 promoter for COX-2 gene. Because, it is described that the level of 
cyclooxygenase-2 enzyme is high in Barrett’s esophagus (BE) epithelium, and also, it is 
shown that COX-2 gene expression is elevated 5-fold in Barrett’s esophagus, so, with regard 
of our results, it can be assumed that the risk of BE developing in the GERD patients with 
COX-2 over expression, after treatment with Omeperazole, might be occurred. This 
hypothesis must be investigated in further study according following up the patients.  
It is shown that G allele at site of -765 promoter for COX-2 gene can reduced COX-2 gene 
expression. Additionally, it is observed that G allele can be changed serum prostaglandin E2 
(PGE2) concentrations. Also, the COX-2 -765G→C polymorphism was demonstrated to 
influence the expression of COX-2 and change the risk of developing adenocarcinoma. 
Chronic inflammation can be developed epithelial hyperplasia, dyslasia, adenoma and 
adenocarcinoma in epithelium of colorectal.  
It is described that COX-2 -765C allele is a protective factor against oral squamous cell 
carcinoma among Taiwan population. However, the COX-2 -765 variants has not effect on 
the risk of head and neck carcinogenesis among Netherland population. Our results showed 
that carriers with C alleles are at higher risk for Gastroesophageal reflux disease (GERD), 
Esophageal squamous cell carcinoma (ESCC) and colorectal cancers. 
It is suggested that genetic variation at -765 of the COX-2 gene may change the over 
expression of COX-2 and therefore result in a higher synthesis of prostaglandins affecting 
the Barrett’s esophagus and carcinogenesis process. In addition, it is described that -765C 
allele of the COX-2 gene affects carcinogenesis of ESCC in Iran. 
Therefore, our ndings can change the direction of future study, focusing on the use of 
therapeutic drugs to control and decrease the risk of gastrointestinal cancers among Iranian 
populations. Degree of COX-2 overexpression may be used as an inducible biomarker for 
detection of risk of malignant transformation in GERD patients. 
5. Conclusion 
It is suggested that identification of COX-2 gene expression and polymorphism at -765 of 
promoter can be used for design of early detection of esophageal cancer and providing 
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prognostic information to GERD patients. Measurement of the degree of COX-2 over 
expression can be used as a biomarker for detection of susceptibility of malignant 
transformation among GERD patients. 
Our study observed the association of the -765C allele carrier genotype with risk for ESCC, 
colorectal cancer and GERD in an Iranian population. Iran has a high incidence of ESCC in 
some parts (Golestan Province) and a young age distribution for colorectal cancer, and 
developing GERD symptoms. The results obtained from such studies can be of great 
importance from a therapeutic point of view, as both groups of cancer cells overexpress 
COX-2 and are more sensitive to COX-2 inhibitors. Further investigation of other cancer 
groups including ADC of the esophagus is required to compare with our results. 
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1. Introduction 
Cancer is the second leading cause of death worldwide. According to the World Health 
Organisation (WHO), 12,5% of all deaths every year are caused by cancer (WHO, 2006). This is 
more than the total percentage of people who die from AIDS, tuberculosis and malaria, put 
together (International Union Against Cancer [UICC], 2007). Frightening fact is that deaths 
from cancer are projected to steadily rise. From about 7,5 million of cancer deaths, registered in 
2005, this number will likely to reach 9 million, in 2015, and about 11,5 million, in 2030 (WHO, 
2006). On the other hand, the knowledge about the causes of cancer and interventions to 
prevent and manage cancer are also growing up very fastly. At the current level of knowledge, 
it is estimated that up to one third of the cancer burden could be reduced if strictly 
implemented preventive strategies aimed at reducing the exposure to cancer risks, and 
another third of this burden could be cured if detected cancer early and treated adequately. 
The term “cancer control“ was coined to unify public health actions aimed at implementing 
evidence-based strategies for cancer prevention, early detection and treatment, however 
adapted to different socioeconomic, cultural and resource settings (WHO, 2006). WHO and its 
cancer research agency, the International Agency for Research in Cancer (IARC), provide 
coordination and the leadership in these international actions (WHO, 2006).  
2. Cancer as a common ageing disease; The risk factors paradigm  
2.1 Cancer as a common ageing disease 
Modern societies are characterised by a domination of chronic noncommunicable diseases in 
morbidity and mortality causes, including cardiovascular diseases, some cancers, chronic 
respiratory diseases, diabetes and dementia. This is partially a consequence of the decline in 
acute infectious diseases, due to improvements in life conditions, sanitation and medical 
care, and partially of the fast spread of modern lifestyles, due to urbanisation, globalisation 
and technology progress (Pearce, 1996, as cited in Majnarić-Trtica, 2009). Modern lifestyles 
include increased consumption of processed foods enriched in saturated fats and sugars, 
smoking cigarettes due to market orientation of tobacco industry, reduced leisure time, use 
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1. Introduction 
Cancer is the second leading cause of death worldwide. According to the World Health 
Organisation (WHO), 12,5% of all deaths every year are caused by cancer (WHO, 2006). This is 
more than the total percentage of people who die from AIDS, tuberculosis and malaria, put 
together (International Union Against Cancer [UICC], 2007). Frightening fact is that deaths 
from cancer are projected to steadily rise. From about 7,5 million of cancer deaths, registered in 
2005, this number will likely to reach 9 million, in 2015, and about 11,5 million, in 2030 (WHO, 
2006). On the other hand, the knowledge about the causes of cancer and interventions to 
prevent and manage cancer are also growing up very fastly. At the current level of knowledge, 
it is estimated that up to one third of the cancer burden could be reduced if strictly 
implemented preventive strategies aimed at reducing the exposure to cancer risks, and 
another third of this burden could be cured if detected cancer early and treated adequately. 
The term “cancer control“ was coined to unify public health actions aimed at implementing 
evidence-based strategies for cancer prevention, early detection and treatment, however 
adapted to different socioeconomic, cultural and resource settings (WHO, 2006). WHO and its 
cancer research agency, the International Agency for Research in Cancer (IARC), provide 
coordination and the leadership in these international actions (WHO, 2006).  
2. Cancer as a common ageing disease; The risk factors paradigm  
2.1 Cancer as a common ageing disease 
Modern societies are characterised by a domination of chronic noncommunicable diseases in 
morbidity and mortality causes, including cardiovascular diseases, some cancers, chronic 
respiratory diseases, diabetes and dementia. This is partially a consequence of the decline in 
acute infectious diseases, due to improvements in life conditions, sanitation and medical 
care, and partially of the fast spread of modern lifestyles, due to urbanisation, globalisation 
and technology progress (Pearce, 1996, as cited in Majnarić-Trtica, 2009). Modern lifestyles 
include increased consumption of processed foods enriched in saturated fats and sugars, 
smoking cigarettes due to market orientation of tobacco industry, reduced leisure time, use 





communication media, all contributing to a sedentary lifestyle and weight gain (American 
Cancer Society [ACS], 2002).  
To prevent diseases, it is necessary to identify and deal with their causes. In the case of 
chronic noncommunicable diseases, that means identification of health risks that underlie 
these diseases (Venkat et al, 2010; WHO, 2009). Most important, in this issue, is that a 
particular disease is caused by multiple risk factors and that, in turn, many risk factors are 
associated with more than one disease. So, by targeting certain risks, it is possible to reduce 
the burden of several diseases (WHO, 2009). This observation is in line with the results of 
the Human Genome Project showing that there is no specific disease susceptibility 
genotype, yet numerous genetic variants account for many age-related phenotypes (Collins 
& McKusick, 2001, as cited in Majnarić-Trtica, 2009; Yang et al., 2003, as cited in Majnarić-
Trtica, 2009). That means that the symptoms and signs of common chronic diseases arise 
from the complex interactions, taking place over time, among multiple genetic variants and 
environmental risk factors, shared between clinically related diseases (Buchanan et al., 2006, 
as cited in Majnarić-Trtica, 2009; Yang et al., 2005, as cited in Majnarić-Trtica, 2008a). The 
main mechanism through which an organism responds to external environmental signals 
was found to be an epigenetic control of genome function in somatic cells (Jaenisch & Bird, 
2003, as cited in Majnarić-Trtica, 2008a; Sandovici, 2008).  
2.2 The risk factors paradigm  
Importantly, when planning preventive activities, is to understand that each risk factor has 
its own causes. In fact, there is a complex chain of events enabling many entry points for 
intervention (WHO, 2009). In the proximity, there are more direct causes of the diseases. 
Factors located further in the back, act through intermediary mechanisms, to produce these 
proximal factors. Causally most distal factors have their background in social conditions 
and are hardly recognisable. However, if modified, these background causes are likely to 
have amplifying effects, by influencing multiple proximal effects (WHO, 2009). Keeping this 
in mind can help health workers and policy makers to realise that besides individually 
oriented preventive measures, population-based strategies are of the greatest importance if 
they want to reduce health risks in a community (American Cancer Society, 2002; WHO, 
2009). That means that an individual choice, regarding health-related behaviors, occurs 
within a community context that can be either facilitating, or interfering with these 
behaviors. For example, in order to disseminate healthy diet and increased physical activity 
patterns, policy makers should implement multiple strategies at the community level, to 
ensure that all population groups have access to healthy food choices and opportunities for 
physical activity (American Cancer Society, 2002).  
Another important fact is that there is no simple correlation between economic development 
and the shift in a major disease burden, from acute infections to chronic noncommunicable 
diseases. Namely, as economic development occurs, tobacco and alcohol use and obesity 
increase, followed by the burden of chronic diseases, in decades later. However, mortality 
and morbidity from chronic diseases do not start to decrease until very high level of social 
and economic development is reached (Derek et al., 2011). In other words, only at a high 
level of awareness about chronic diseases, governments and policy makers are likely to 
respond on negative trends in health behaviors, by using a range of policy instruments to 
revert these trends. It is not surprisingly then, that in the coming decades, the burden from 
chronic diseases is projected to rise, particularly fast in the developing world (Daar et al., 
 
Prevention and Early Detection of Cancer – A Public Health View 
 
15 
2007). However, chronic diseases do not simple replace acute infections; rather, developing 
countries experience double disease burden, that have a huge negative impact on their 
economies (Derek et al., 2011; Daar et al., 2007). 
By attributing known risk factors, including behavioural, physiological, occupational and 
environmental ones, to the total number of deaths, or the burden of diseases (measured in 
DALYs - years of life lost due to premature mortality and disability), it is possible to 
estimate of how much the burden of diseases is attributable to these selected risk factors 
(Venkat et al. 2010; WHO, 2009). Based on such analysis, it was realised that more than one 
third of the world`s deaths can be attributed to a small number of risk factors. The five top-
ranked risks include high blood pressure, tobacco use, high blood glucose, physical 
inactivity and overweight/obesity. They affect countries of all income groups: high, middle 
and low (Figure 1) (WHO, 2009). When taking into account the fact that two leading world`s 
causes of death include cardiovascular diseases and cancers, this is likely to suggest that 
avoiding tobacco and obesity, and using regular physical activity, can provide the greatest 
potential to minimise cancer risk (American Cancer Society, 2002; WHO, 2009).  
 
Fig. 1. Deaths attributed to leading risk factors, by country income level (2004) 
3. Cancer with infectious origin 
It is estimated that approximately 15% of all cancers can be attributed to viral infections. The 
oncogenic role of at least six viruses has strongly been established, including Epstein-Barr 
virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), several Human 
Papillomavirus (HPV) types, Human T-cell Lymphotropic Virus type I (HTLV-I) and 
Human Immunodeficiency Virus type I (HIV-I) (Boccardo & Villa, 2011). Cells infected by 
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depending on the contextual, both the host-related, and the environmental factors - the fact 
that may complicate targeting potential preventive and therapeutic approaches (Butel, 1999; 
Weinberg, 1994). On the other hand, knowledge about the ways these infections are being 
spreaded on, is likely to provide directions for instituting adequate infection control 
practices. In relation to this, it is known that some of these infections are sexually 
transmitted and can be attributed to unsafe sex and non-use of contraception. Others are 
associated with using nonsterilised injection equipment, that is either related to unsafe 
health-care, or to opiates addiction (Boccardo & Villa, 2011; WHO, 2009).  
The great opportunity for cancer prevention, at the global scale, lies in the development and 
distribution of antiviral vaccines (Schiller & Lowy, 2010). Commercially available HBV and 
HPV vaccines are already in use, and the major focus is now on their delivery, especially to 
low-income countries (Dempsey, 2010; El-Serag, 2011). The reasoning is based on the fact 
showing that HBV infection accounts for about 60% of the total liver cancer in developing 
countries, while for only about 23% in developed countries. For cervical cancer (HPV 
infection was proved as a course), the third most commonly diagnosed cancer and the 
fourth leading cause of cancer death in females worldwide, more than 85% of all cases and 
deaths occur in developing countries (Ferlay, 2010; WHO, 2009).  
4. Environmental pollution and industrial carcinogenes 
The discovery of smoking tobacco as a factor being strongly associated with lung cancer 
(more than 85% of lung cancers occur among smokers), has further emphasized the 
definition of other external factors that could probable cause cancer (that are termed 
“carcinogenes“) (American Cancer Society, 2007, as cited in Majnarić-Trtica, 2009; Pearce, 
1996, as cited in Majnarić-Trtica, 2009).  
Accordingly, at least 150 chemicals and other agents, including ionizing radiation, 
occupational (workplace) and environmental airborne particles, some drugs, as well as 
foods and other consumer products, have been listed so far by IARC, as potential 
carcinogens (American Cancer Society, 2007, as cited in Majnarić-Trtica, 2009; WHO, 2009). 
It is estimated, for example, that occupational exposure to microscopic airborne particles 
accounts for 8% of lung cancer, that is the most frequent form of occupational cancer 
(compared to 12% of deaths due to chronic obstructive pulmonary disease) (WHO, 2009). 
The encouraging fact is, however, that the majority of occupational cancers can be 
prevented, through minimising exposure, substituting safer materials, and/or enclosing 
processes and ventilation. These all are measures within the domain of engineering 
manipulation, and policy and legislation changes (WHO, 2009).  
Trends which deserve particular concern of the scientists, policy-makers and the public as a 
whole, are based on the growing number of evidence showing that long-term exposure to 
traffic-related air pollution is the risk factor which can contribute to overall and especially to 
specific respiratory and cardiovascular mortality in general population (Brunekreef et al., 
2009). Even some consumer products, including food, cosmetics and household cleaners, 
owing to their overall use, are among the most significant sources of exposure to toxic and 
carcinogenic chemicals. Higher level of awareness is the first step to tackle more adequate 
legislation and adversiting options, as well as technology innovations (American Cancer 
Society, 2007, as cited in Majnarić-Trtica, 2009; WHO, 2009).  
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5. Global cancer statistics and calls for action 
5.1 Global cancer statistics 
Based on the GLOBOCAN estimates, about 12,7 million cancer cases and 7,6 million cancer 
deaths occured worldwide in 2008 and this trend continues to rise (Jemal et al., 2011). 
Proposed major reasons include: 1) the ageing, alongside with growth, of the world 
population, as cancer affects older adults at the highest rates, and 2) an increasing adoption 
of cancer-causing behaviors, due to the processes of modernisation and globalisation (Jemal 
et al., 2011; WHO, 2009). Of this total cancer burden, 56% of the cases and 64% of the deaths 
have occured in the economically developing world. Although overall cancer incidence rates 
in the developing countries are half those registred in the developed world, the cancer 
mortality is generally similar (Jemal et al., 2011). The main reason for this dysproportion is 
in cancer survival rates, which tend to be poor in developing countries, mostly because of a 
late stage at diagnosis and limited access to timely and standard treatment (American 
Cancer Society, 2007, as cited in Majnarić-Trtica, 2008b; Jemal et al., 2011; Ebling et al., 1993, 
as cited in Majnarić-Trtica et al., 2008b).  
The most frequent cancer site diagnosed in females worldwide is breast cancer and it is also 
the leading cause of cancer death, comprising 23% of the total cancer cases and 14% of the 
cancer deaths. In general, the highest incidence rates are registered in the most developed 
regions, although 60% of the deaths occur in developing countries. Brest cancer is now the 
leading cause of cancer death among females in developing countries, a shift from cervical 
cancer which held this unfavorable position in the past decades. The second and the third 
most frequently diagnosed cancers in females are colorectal and lung cancers, the reverse 
order in cancer mortality (Table 1) (Jemal et al., 2011).  
 
Table 1. Leading cancer incidence and mortality rates, females, for more and less developed 
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In males, the most common cancer site and the leading cause of cancer death is lung cancer, 
comprising 17% of the cancer cases and 23% of the cancer death (Table 2). Colorectal and 
prostate cancers are at the second and the third positions in cancer incidence and follow the 
same order in cancer mortality, with the addition of stomach cancer sharing the third 
position with prostate cancer (Jemal et al., 2011).  
 
Table 2. Leading cancer incidence and mortality rates, males, for more and less developed 
areas, world (GLOBOCAN 2008)  
5.2 Calls for action 
Based on the global cancer statistics, awareness is growing that a dramatic stride in fighting 
against cancer can be done only if initiatives are planned at the global scale. The framework 
for this call for a global action is provided in the form of basic documents, such as World 
Cancer Declaration 2006 (IUCC, 2006). According to this document, the aim is to increase the 
number of countries that have the national cancer control programs, including cancer 
prevention, early detection, treatment, palliative care and support for cancer patients. 
Cancer surveillance systems, including cancer registries, should be developed if they do not 
exist, to support data collection on cancer statistics, risk factors burden, and effects of 
measures done. Lower income countries will be especially encouraged to gain abilities for 
dealing with their growing cancer burden. In order to transfer the proclaimed aims into 
practice, international committees have established cancer control strategies (WHO, 2005, as 
cited in Majnarić-Trtica, 2008b).  
5.3 The state in EU 
In the European Union (EU27), 2,5 million of people were diagnosed with cancer in 2008 
(Ferlay, 2010). During the past decades, cooperation at the EU level showed that it is possible 
to add value, beyond the national level, to reduce cancer burden in Europe. The goal, set under 
the Commission`s “Europe Against Cancer“ programs (1987-2000), was a 15% reduction in 
cancer mortality by 2000 (Moss, 2000, as cited in Majnarić-Trtica, 2008b). Until 2003, the 
Program was at the half of this proposed pathway, with registered reduction of 9% (Boyle et 
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al., 2003). Until 2008, some of the Member States, like Finland and Luxemburg and Austria, 
have yet succeed in their efforts to reach this proclaimed goal (Cancer Society of Finland, 
2010). The horizontal approach, aimed at tackling major health cancer-causing determinants, is 
being accomplished through documents such as “European Environment and Health Action 
Plan (2004)“, set up in order to minimise work-related exposures to carcinogens and 
mutagens, and “the European Code Against Cancer“ (2003), set up to promote healthy 
lifestyles (as cited in Commission of the European Communities, 2009).  
In general, although significant advances have been made in cancer control, cancer is still a 
major public health concern in EU, accounting for 29% (3 out of 10) of deaths in men and 
23% (2 out of 10) of deaths in women (the facts for 2008) (European Commission, 2011).  
Nowadays, the situation is characterised with substantial inequalities in cancer control 
among Member States, that is illustrated with the fact that mortality from cervical cancer is 
nearly four times, and mortality from lung cancer, in men - over three times higher, in the 
worst performing Member States, than in the best ones (European Commission, 2011). In 
order to strengthen efforts to share information, capacity and expertise in cancer prevention 
and control, the European Commission has recently proposed the “European Partnership 
for Action Against Cancer“, for the period 2009-2013 (Commission of the European 
Communities, 2009).  
6. Preventive measures that can reduce the cancer burden 
Based on the experience gained so far, it is considered that a substantial proportion of the 
cancer burden worldwide could be prevented if adequately implemented community-based 
programs for early cancer detection and treatment, tobacco control, cancer-related vaccination 
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 Implementation of principles of a healthy life-style, mainly by means of a healthy 
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 Changes in sexual behaviour (including the number of partners, partners selection, 
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 Immunization against Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) 
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 Avoidance of cancer-causing substances in the global environment and in consumer 
products 
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cited in Majnarić-Trtica et al., 2008b). Results of randomised trials and experience of the 
countries where national programs for prevention and early detection of cancer have been 
implemented, showed that the implementation of such programs, especially when they are 
well prepared and monitored, is the most efficient and, in the long run, the least costly 
approach to fight cancer (Levin, B., et al., 2003, Nystrom, L., 2002, as cited in Majnarić-Trtica, 
2008b). Based on these facts, respective agencies, such as the American Cancer Society, 
United States Preventive Services Task Force (USPSTF), WHO, and the European Union 
Advisory Committee on Cancer Prevention (EUACCP), set up recommendations for the 
early detection of cancer (American Cancer Society Guidelines for the Early Detection of 
Cancer, 2007, The Council of the European Union Recommendation of 2 December 2003 on 
cancer screening (2003/878/EC), 2003, WHO Program on Cancer Control, 2003, as cited in 
Majnarić-Trtica, 2008b).  
In principle, these programs may be two-way oriented. One way is promotion of the early 
diagnosis by recognising the early clinical symptoms and signs of cancer, based on health 
education programs performed for both, primary health care physicians and the population 
(WHO/Cancer, 2007, Wender, R.C., 2007, as cited in Majnarić-Trtica, 2008b). The other way 
is screening of an apparently healthy population, before clinical signs of cancer are 
detectable, in order to find individuals with the early cancer or pre-cancer stages (Moss, S., 
2000, as cited in Majnarić-Trtica, 2008b). In this sense, screening procedures are considered 
as measures of a secondary prevention. There are two main approaches for targeting 
population: 1) targeting high-risk people (with a lifetime risk of getting a certain type of 
cancer of at least 20 to 25%), who are most likely to benefit from the intervention, and 2) 
targeting risk in the entire population, regardless of each individual`s risk and potential 
benefit (WHO, 2009).  
Fundamental for the screening is availability of effective (with the acceptable level of 
sensitivity and specificity), low-cost, simple for application, and safe tests. This is not 
possible for all cancer sites. Fortunately, screening tests proved so far as being feasible for 
wide implementation, correspond with some of the most frequent cancer sites. These tests 
include: high-quality mammography (for breast cancer), Pap cytology test (for cervical 
cancer) and testing for occult faecal bleeding (for colorectal cancer) (American Cancer 
Society Guidelines for the Early Detection of Cancer, 2007, as cited in Majnarić-Trtica, 
2008b). The screening of prostate cancer by using prostate-specific antigen (PSA) testing has 
not yet been established routinely on a population base, although the increasing amount of 
evidence confirms that the early detection of this main form of cancer in men considerably 
reduces mortality, increases survival, and is likely to be cost-effective (American Cancer 
Society Guidelines for the Early Detection of Cancer, 2007; The Council of the EU, 2003, as 
cited in Majnarić-Trtica, 2008b; ESMO Guidelines Working Group, 2011).  
Under the influence of the rapid technology progress and a large amount of randomised 
trials in which the validity of particular screening approaches have been assessed - 
screening methods and protocols are constantly being changed (Table 4) (American Cancer 
Society Guidelines for the Early Detection of Cancer, 2008). Efforts have also been made in 
looking for appropriate methods for the early detection of some other frequent and/or 
hazardous cancer sites, such as lung cancer, or pancreatic cancer (Harold, C.S., 2011; The Sol 
Goldman Pancreatic Cancer Research Center, 2011).  
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replacement therapy, Western-style diet, obesity, and consuming alcohol and tobacco 
among women (Aebi, 2011; Warner, 2011). Although it is still the leading cause of cancer-
related deaths in women, in most Western countries, the mortality trend has been 
decreasing in recent years, partly due to the screening programs implementation, and partly 
due to the improvements in treatment (Ferlay, 2010).  
 
Table 5. Costs associated with mammography 
It is estimated that over 90% of breast cancer in women can be cured if a disease is 
diagnosed in an early stage and adequately treated (American Cancer Society Guidelines for 
the Early Detection of Cancer, 2007, as cited in Majnarić-Trtica, 2008b). Several procedures 
are routinely used to diagnose breast cancer, including clinical (breast self-examination and 
bimanual palpation of the breasts and regional lymph nodes peformed by health care 
professionals), radiological (bilateral mammography and ultrasound) and pathological 
examination (based on the core needle biopsy). Some advanced imaging techniques, such as 
MRI (magnetic resonance imaging) and digital mammography, have recently been added, 
because of high diagnostic sensitivity of these methods (Warner, 2011). However, 
mammography is the only screening method to date proved as to can reduce mortality from 
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breast cancer, and any other method can be used only as a supplement to mammography 
(Warner, 2011). For reading of mammograms, BI-RADS classification (stages 0-5) is used. 
Cases suspected on cancer (BI-RADS 4 or 5) are refered for follow up (Eberl, 2006).  
Breast cancer incidence is strongly age-dependent, with only a quarter of cases occuring 
before age 50; less than 5% before age 35 (Ferlay, 2010). Based on these facts and on the 
results from randomised trials which consistently show a 14% to 32% reduction in mortality 
from breast cancer with annual or biennial mammography in women 50 to 69 years of age, 
screening mammography is universally recommended for women 50-69 years of age, with a 
1-year, or 2-year screening interval (Nystrom, 2002, as cited in Majnarić-Trtica, 2008b; 
Warner, 2011). Some guidelines also include women aged 40-49, although data on the 
benefit to cost ratio have not yet been clarified (Table 4) (Mandelblatt, 2011; Warner, 2011).  
Based on accumulated evidence, the decision to screen, more and more involves weighting 
benefits against costs (Table 5) (Warner, 2011). In the case of screening mammography, the 
most important benefits include reduction in the risk of death and the number of life-years 
gained. Costs include the financial costs and the by-products of the screening regimen itself 
(radiation risk, pain, inconvenience and anxiety), false positive and false negative results, as 
well as overdiagnosis (leading to overtreatment) (Duffy, 2010; Warner, 2011). The ratio of 
benefit to cost varies significantly with the patient`s age and depends on some other 
patient`s characteristics, such as breasts density (Warner, 2011). New, revised guidelines for 
breast cancer screening therefore tend to be more individually oriented.  
7.2 Screening of cervical cancer  
Cervical cancer is the third most common cause of female mortality worldwide, with the 
mortality rate 10 times higher in developing countries, and 80% of new cases occuring in 
these regions, compared to the developed countries (Ferlay, 2010; Haie-Meder, 2010). This 
disparity is in connection with low level of knowledge about unsafe sex and inaccessibility 
to screening and treatment programs, for women in developing countries (Ferlay, 2010; 
WHO, 2009). The main problem, in developed countries, is still insufficient coverage of 
women in the generative age with the screening test (Commission of the European Union, 
2007; Haie-Meder, 2010).  
Cervical cytology based on Pap smears remains the cornerstone of cervical cancer 
prevention programs, although this filed has rapidly been developing due to improved 
understanding of the natural history of the disease and technology innovations, such as 
liquid-based cytology, automated interpretation of Pap smears and testing for human 
papillomaviruses (HPVs) (American Cancer Society Guidelines, 2011; ESMO European 
guidelines for quality assurance, 2010). This, on the one hand, points up the neccessity for 
establishing the uniform indicators for monitoring program performance, to enable data 
comparison across the countries, and on the other hand - leads to fast exchanges of practice 
guidelines (Table 4) (ESMO European guidelines for quality assurance, 2010).  
It is now well known that a persistent infection with sexually transmittable human 
papillomaviruses is responsible for virtually all cases of cervical cancer (Haie-Meder, 2010). 
Early age at first sexual intercourse and early pregnancies have been recognised as risk 
factors. The evidence linking HPV infection to cervical cancer has initiated the development 
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conventional Papanicolaou smear testing (Figure 2) (American Cancer Society Guidelines, 
2011; ESMO European guidelines for quality assurance, 2010). Also, primary prevention by 
prophylactic vaccination against the HPV types that are causally linked with most cervical 
cancers in Europe, HPV-16 and HPV-18, is now commercially available (Schiller & Lowy, 
2010). The high efficacy of the vaccines is expected to dramatically decrease cervical cancer, 
by preventing up to 70% of newly diagnosed cases. However, prophylactic vaccination is 
performed in young girls and it will take a time until it provides the health gains. Therefore, 
cervical screening still remains the main preventive option (Figure 2). Nowadays, situation 
is that the high cost of the vaccine prevents its widespread implementation, which may 
further increase the gap in cervical cancer statistics between developed and developing 
countries (Haie-Meder, 2010).  
 
Fig. 2. Combined strategies to decrease cervical cancer 
7.3 Screening of colorectal cancer 
Cancers of the colon and rectum altogether are the third most common cancer type in the 
world and the most common newly diagnosed cancer in EU (Ferlay, 2010). In general, 
incidence is increasing along with industrialisation and urbanisation and is slightly higher 
in western and central, than in northern and southern and eastern Europe (Labianca, 2010).  
Five-year survival rates, after the disease is detected, is much worse in the Eastern European 
countries, then in the developed countries (34%, compared to 54% and 65%, in the Western 
European countries and the USA, respectively) (Ferlay, 2010). As the result of the early 
detection programs implementation in many EU countries, in past decades, five-year 
survival rates show more favourable trends in all regions of Europe, compared to as it was 
before (Labianca, 2010).  
Strong genetic influence can be attributed to only 5%-10% of colorectal cancers cases, due to 
either polyposis or non-polyposis syndromes, while the majority of cases occur sporadically 
(Balmana, 2010). The most important exogenous factors identified so far include: western-
style diet and low physical activity, smoking tobacco and inflammatory bowel diseases, 
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while the effect of chronic use of non-steroidal anti-inflammatory drugs for the prevention 
or regression of colorectal adenomas, has not yet been strongly confirmed (Labianca, 2010).  
If take into account fact that a 10-35 years long-lasting period is needed for the transformation 
of benign adenomas to cancer, it seems reasonable to expect that the systematic 
implementation of the programs of active searching for subjects with localised cancer or pre-
cancer lesions, could substantially reduce colorectal cancer mortality rate in population. It is 
estimated that under these conditions, colorectal cancer could reach a high cure rate of 80% 
and more (Winawer, 2003, as cited in Majnarić-Trtica, 2008b). This makes colorectal cancer an 
ideal candidate for screening. Since about 70% of patients are >65 y of age and the disease is 
rare under the age of 45 (2 per 100 000/y), target groups for screening usually include 
population aged 50-74y, with the minimum recommendations for the age range 60-69y 
(American Cancer Society Guidelines, 2011; Labianca, 2010). In order to complement 
community-based screening programs for breast and cervical cancers, established in many EU 
countries several decades ago, the EU Commision set up in 2003 recommendations for early 
detection of colorectal cancer, and the action plan “Europe against Colon Cancer“, based on 
“the Brussels Declaration“ (IUCC/Interantional Union against cancer, 2007, WHO/WHO 
Cancer Control Strategy, 2005, as cited in Majnarić-Trtica, 2008b).  
 
*Based on an uptake rate of 78% 
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Up to date, two strategies have been available: faecal occult blood test (FOBT) and 
endoscopy (colonoscopy or proctosigmoidoscopy) (American Cancer Society Guidelines for 
the Early Detection of Cancer, 2007, BMJ Clin Evid Concise/Colorectal cancer screening, 
2006, as cited in Majnarić-Trtica, 2008b; Labianca, 2010). Experiences on using the 
conventional screening method, the Faecal Occult Blood Test (FOBT), applied in 
asymptomatic population at average risk, showed that 3-5% subjects with positive results 
are to be expected (Winawer, 2003; Bond, 2006, as cited in Majnarić-Trtica, 2008b). The 
rationale for its use is based on the fact that, at an early stage, a colorectal tumour causes 
minor bleeding which can not be seen with the naked eye. The purpose of the screening is to 
check for this hidden blood in the stool sample. Recently introduced, the Faecal 
Immunochemical Test (FIT), has been shown as simpler for use and of a better specificity, 
however, because of higher price and the lack of efficiency analysis, it has not been yet 
widely implementated (American Cancer Society Guidelines, 2011). In most 
recommendations, the FOBT is used as a standard screening method, and a colonoscopy - 
for follow-up of test-positive cases. Based on widely obtained data, 10-15% of those subjects 
referred to colonoscopy are expected to be diagnosed as cancer and 30-40% as adenomas 
(Figure 3) (American Cancer Society Five-Year Relative Survival Rates, 2007, as cited in 
Majnarić-Trtica, 2008b; NHS.UK, 2011). Experiences until now showed that if screening 
strategies are implemented as organised programs based on the screening interval of 1-2 
years, it is possible to reduce mortality rate for 18% -33% (Achkar, 2006, as cited in Majnarić-
Trtica, 2008b).  
7.4 Screening of prostate cancer 
Prostate cancer is one of the three major cancer sites in men; commonly occures after 50 
years of age, with incidence progressively increasing in later decades of life. Only males 
with positive family history of a disease (at least one blood relative: father, grandfather, or 
brother) are at a higher risk even in age before 50 (American Cancer Society Guidelines for 
the Early Detection of Prostate Cancer, 2011; ESMO Guidelines Working Group, 2011).  
Screening protocol include digitorectal examination (DRE) and PSA (prostate-specific-
antigen) measuring in serum, in patients aged ≥50 years, in those who refer symptoms of 
prostatism and urinary tract disorders, or in those who require screening. The decision on 
whether or not to have a prostate biopsy (performed by transrectal ultrasound, TRUS) 
should take into account PSA parameters, such as free (f) PSA, fPSA/PSA ratio, DRE 
findings, prostate size, patient age, comorbidities, patient values and history of previous 
biopsy (American Cancer Society Guidelines for the Early Detection of Prostate Cancer, 
2011; ESMO Guidelines Working Group, 2011).  
Although there are evidence indicating that population-based screening may reduce 
prostate cancer mortality by approximately 20%, patients should have an opportunity to 
make an informed decision on whether to be screened or not, since there are some 
uncertainties associated with prostate cancer screening (American Cancer Society 
Guidelines for the Early Detection of Prostate Cancer, 2011; ESMO Guidelines Working 
Group, 2011). Namely, screening increases prostate cancer incidence, including subclinical 
forms that will not develop during life, leading to unnecessary manipulation and 
overtreating. Long prospective studies, and cost-effectiveness and quality of life analyses, 
 
Prevention and Early Detection of Cancer – A Public Health View 
 
27 
which are now under way, are expected to justify decisions on population screening on 
prostate cancer.  
8. Programs of early cancer detection  
In a general sense, screening program means systematic examination of the defined target 
population at average risk for developing some hazardous disease or undesirable medical 
event, or using scientifically justified tests that are appropriate to be applied as a public 
health measure (Table 6). Screening is organised periodically and at a long run, with the 
clearly defined aim to reduce the population burden of a disease and its unfavourable 
effects on the national health care system and economy. All activities in the program are 
fairly planned in an advance and performed according to the up to date standards of a 
medical care, with external finance assured. They include several subsequent steps, from 
promotional and educational activities, to screening, and a referal of subjects tested positive 
for further diagnostics and treatment. In concern to cancer, the early detection program is 
tending to become a part of more comprehensivelly shaped national strategies for cancer 
control, including also primary prevention and health promotion, as well as rehabilitation of 
cured patients, and palliative care for patients with infaust prognosis (WHO/Cancer, 2006). 
A programed approach has been proved as more efficient than the opposite one - an 
opportunistic approach - based mostly on patients demand, or performed in a diagnostic or 
clinical context. In the latter case, examinations may or may not be performed according to 
the public screening policy (Cancer screening in EU, 2007).  
There is a wide consensus that a minimum degree of public responsibility, organisation and 
supervision, is required, for screening activities to be considered as within the context of a 
program, in opposite to a “non-program“ screening. To qualify as a program, there should 
be a public screening policy documented in a law, or an official regulation, directive, or 
recommendation. As a minimum, the policy should define the screening test, the 
examination intervals, and the group of subjects eligible to be screened, including finance 
from public sources, or a co-payment. In a reality, substantially more organisational 
elements are needed to qualify screening activities as an “organised program“. These 
elements provide for supervision and monitoring of most steps in the screening process, as 
well as comprehensive guidelines and rules to define standard operation procedures. In fact, 
differentiation of “organised“ from “unorganised“ programs should take into account the 
continuous gradient, ranging from poorly organised to highly organised programs. Further, 
a team, or the body, declared as being responsible for program`s implementation and 
coordination, can be organised at the regional or national level. Programs may be further 
differentiated as to whether they are population-based or non-population-based. 
Population-based programs generally require a high degree of organisation and that, in each 
round of screening, subjects from the taget population are individually identified and 
personally invited to screening. Finally, in the case of population-based screening, program 
implementation may be in various stages of development: planning phase, pilot phase, 
rollout ongoing, or rollout complete (i.e. fully established) (Figure 4) (Cancer screening in 
EU, 2007).  
During last decades, evidence has been gained, in several countries in Europe, including 
Finland, Sweden, UK and Netherlands, which programs were performed to give 
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organised programs for early cancer detection (Cancer Society of Finland/Screening 
programme, 2011).  
 the condition is an important health problem 
 its natural history is well understood 
 it is recognisable at an early stage 
 treatment is better at an early stage 
 a suitable test exists 
 an acceptable test exists 
 adequate facilities exist to cope with abnormalities detected 
 screening is done at repeate intervals when the onset is insidious 
 the chance of harm is less than the chance of benefit 
 the cost is balanced against benefit 
Table 6. Ten principles which should govern a national screening program (by Wilson and 
Jungner of the WHO, 1968) 
 
Fig. 4. Screening programs implemantation in the EU, breast and colorectal cancers, for 
usual target groups 
Until 2007, 22 Member States (out of 27) have adopted policies aiming for implementation of 
population-based screening programs, 11 of them in which nationwide rollout of 
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population-based programs is complete, 7 in which it is ongoing, and 4 in which it is being 
piloted or planned. Cervical cancer screening programs were running or being established 
in 25 of the Member States, but in comparison to the situation with breast cancer screening, 
program implementation varies more markedly and there is a substantial deviation from the 
recommendations of the Council of the EU. Compared to the prior two, colorectal cancer 
screening programs were running or being established in a smaller number of the Member 
States, program implementation was less advanced, and a smaller proportion of the 
population, specified in the Council Recommendations, was targeted (Figure 4) (Cancer 
screening in EU, 2010).  
8.1 Programs of some European countries  
8.1.1 Finland 
In Finland, population-based cancer screening has a long tradition, as started in the far 1963 
with cervical cancer screening (Cancer Society of Finland/Screening programme, 2011). 
Over the years, this program has come under the scrutiny, and now serves as a gold 
standard for evaluation of screening programs` quality and effectiveness. Two other main 
cancer screenings, for breast and colorectal cancer, are also being carried out in a highly 
organised manner. The first started in 1987, and the latter in 2004, after the EU Commission 
set up in 2003 its recommendations for strenghtening the efforts over early detection of 
colorectal cancer. The Mass Screening Registry provides evaluation of the impact of 
screening programs on cancer-related mortality and of the quality of the screening 
programs, and is a complementary to the Finnish Cancer Registry. The Finnish Cancer 
Registry is currently included in the European trial on prostate cancer screening.  
Screening programs are centrally directed by the Cancer Society of Finland, but it does not 
exclude regional societies to work independently and to adjust programs to different local 
environments. These regional organisations provide a vast array of services, including 
counselling units, ambulatory cancer clinics, laboratories and hospices, as well as 
organisation of rehabilitation and recreational courses. Patient organisations and numerous 
volunteers, joined as members, provide the popular base to the Societies. The Cancer 
Society, together with the Cancer Foundation and the Foundation for Cancer Research, as 
private, non-profit investors, provide the sources of funds aimed at preventing cancer 
through research, health promotion and mass screenings. The Society also actively 
participates in creating health policy. In this way, the Cancer Society has become a vast 
forum for providing a support to comprehensive cancer control, by bringing together 
scientists, clinicians, decision-makers, financial experts, volunteers and patients, in the 
common mission of reducing the cancer burden in the population.  
Specifically, Finnish smoking prevention and cessation campaigns, are worth meantioning 
details. Cigarette consumption in Finland was the highest in the world, in the period 
between two wars; consequently, the lung cancer incidence in men was one of the highest in 
the world. Due to combined effect of legislative measures, health promotion activities and 
strict monitoring, smoking decreased drastically over time, and nowadays is among the 
lowest in Europe.  
By acting in this way, Finland has become one of the leading European countries in 
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the five-year survival rates among the best in Europe. Overall, in performing public health 
activities, Finland experienced a long process of transition, from the prevailing implicit 
policies, determined by commercial and fiscal interest, to explicit - health-oriented polices. 
In this context, earlier, the risk behaviour and a disease concern was considered as a medical 
and individual problem, while nowadays it is primarily considered as a public health, social 
and political issue.  
8.1.2 UK 
National cancer screening programs in UK include cervical, breast and colorectal cancers. 
For prostate cancer, there is an informed choice program - for healthy men who requires 
screening, and the risk management program - for men at higher risk for developing 
disease, due to symptoms of prostatism, or a positive family history on prostate cancer 
(NHS.UK, 2011). Cancer screening programs in UK are characterised with a high level of 
quality performance, and a large coverage of the target population, for cervical cancer 
already reaching the expected 80% (Arbyn, 2008, as cited in NHS.UK, 2011). Further, these 
programs are strictly evidence based, by means of the screening intervals, recommended 
age groups and methods used for screening. To avoid disparities for screening, community-
driven approach is prefered, while Primary Care Trusts and regional directors of public 
healths are responsible for the quality assurance. The National Office for Cancer Screening 
provides the call/recall system and coordinate all other activities (NHS.UK, 2011).  
The main shortage of this system is in using the lists of patients registered with general 
practitioners (GPs), allowing eligible individuals not covered by the health insurance, to 
drop out from the screening. The UK is an example of the cancer screening model which in a 
great part relies on the ordinary health care facilities and includes primary care teams to 
participate, by encouraging patients to screening and by keeping them informed on all the 
stages of the screening program. This model is termed as a “model service“.  
8.1.3 Hungary 
Hungary, as a state in the process of transition, is typically faced with the growing burden of 
chronic noncommunicable diseases, especially concerning cancer (Kovacs, 2011, as cited in 
Hčjz/Health in Hungary). The life expectancy, of both men and women, is significantly 
below the average of most countries in EU, with cancer at the leading position in regard to 
“potential year of life lost“ (PYLL). With the aim to reduce the overall mortality, and cancer 
mortality in particular, an organised cancer screening program, a part of the National Public 
Health Program, was launched in 2001. The official health care system is responsible for the 
program implementation, and finances are assured by the government. The program is 
coordinated and monitored by the Office of Chief Medical Officer.  
Analysis made upon the program implementation, reveales some shortcomings, similar to 
ones found in other programs with small tradition. Some of these barriers to program`s 
implementation include the lack of necessary prerequisites for screening, insufficient 
finances, and a fairly high number of screenings performed outside the organised screening 
settings. The latter phenomenon may be due to the low degree of awareness for mass 
screenings, and to the fixation upon traditional examination protocols. Further, there is a 
poor cooperation among acters within the programs, the problem in record linkage, between 
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various databases, and yet undeveloped laws on sensitive issues, such as data protection 
and patients rights (Kovacs, 2011, as cited in CJPH/Health in Hungary).  
8.1.4 Croatian national program of prevention and early detection of cancer 
Croatia is a transitional country characterised with health problems such as unhealthy 
behavior of the population and a growing burden of chronic diseases. The situation is even 
worse than it could be expected, because Croatia has recently experienced a war and fast 
political and social changes (Ebling B., 2007; Majnarić-Trtica, 2009).  
In cancer statistics, in comparison with the majority of European countries, Croatia takes 
high unfavourable position (Draft National Program, 2007). Cancer is the second mortality 
cause and accounts for every fourth case of death. Both cancer incidence and mortality rates 
are on the increase, with a sharp increase in incidence rates observed after 1997, 
consequently to the post war period (Figure 5). The most common cancer sites are the lung, 
the colon and the breast, with the prostate cancer prevailing in elderly men aged 75 and 
more.  
 
Fig. 5. Total cancer incidence and mortality rates, Croatia  
In Croatia, primary prevention and early detection of cancer have not been systematically 
performed before, except for some separate actions, carried out by the non-governmental 
organisations or professional associations (Eljuga, 2006, as cited in Majnarić-Trtica, 2008b). 
The early detection of cervical cancer, by cervical cytology, has been performing for all 
sexually active women during their visits to gynecologists (Šamija, ed., 2000, as cited in 
Majnarić-Trtica, 2008b). Clinical examination on cancer and the FOBT have become a part of 
periodical medical checks, performed by family physicians for patients aged 50 and older.  
Based on such situation and by taking into account unfavourable cancer statistics, the 
Croatian Oncology Society of the Croatian Medical Association initiated preparation of a 
Draft National Program for Prevention and Early Detection of Cancer (Draft National 
Program, 2007). The Program was published in early 2006. On behalf of the Ministry of 
Health and Social Welfare, the breast cancer screening program has started immediately that 
year. The National Program for Early Detection of Colorectal Cancer has started in late 2007. 
The Croatian Public Health Institute and its county departments coordinate and monitor 
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collection and evaluation. Family medicine teams are not actively included, only in keeping 
data on responsiveness of their invited patients to screening, and in follow up of those ones 
with positive tests.  
General objectives, set up by the Program, are: to decrease prevalence of risk factors among 
the population by promotional and health educational activities, to reduce total cancer-
related mortality rates by 15% within 5 years after the Program started, to increase the 
percentage of diagnosed pre-clinical and localised cancers compared to percentage of 
advanced stage disease and to increase the early detection coverage of the population. 
Specific objectives are oriented towards improvements in diagnostics and treatment and 
standardisation of protocols (Table 7).  
 
Table 7. Croatian National Program, Recommendations for screening 
According to the Program for Early detection of breast cancer, women of the target 
population (50-69) are invited by surface mail to take preventive mammography every two 
years. Based on the planned coverage of 70%, it amounts about 280 000 women a year. BI-
RADS classification and double-blind reading performed by two experienced radiologists 
are used as methods for checking up mammograms. Cases suspected on cancer (BI-RADS 4 
and 5) are refered for follow up (Draft National Program, 2007; Ministry of health, 2006). 
In the first screening cycle (until the end of 2006), about 720 000 women were invited, the 
number exceeded the planned number of 280 000 invitations a year, with more than 1500 
newly diagnosed cases. (Experience from other European countries also showed increase in 
the cancer incidence during the first year of screening program implementation). Although 
achieved response rate of 58,5% was comparable to that in other European countries, the 
authorities are not completely satisfied with the results (Strnad, 2010). As the main barriers 
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to program implementation, wrong addresses and insufficiently checked patients lists, were 
addressed. The rate of suspicious results was lower than expected, which indicates that 
women with BI-RADS 0 should also be taken into consideration for referal to diagnostics. 
Continuous education of radiologists in reading the mammograms and acquisition of new 
equipments for the diagnostic centres, are planned improvement measures. Educational 
activities, with the aim to increase the level of awareness for screening among the 
population, and further strenghtening the knowledge and companionships, as much among 
different sectors and participants included in the Project, as among local communities, will 
be essential (Samardžić, 2007; Strnad, 2010).  
The screening protocol for colon cancer includes assimptomatic men and women aged 50-74 
years, as according to the international recommendations, in two-year check-up by the 
FOBT, and the coverage rate of at least 60%. Test-positive individuals are referred to 
colonoscopy, to determine the cause of occult faecal bleeding. Individuals from the high risk 
groups are managed following the special protocols. Specialists colonoscopists and surgeons 
from clinical hospitals, and laboratory workers and coordinators from the counties` Public 
Health Institutes, are responsible for the Program implementation. Invitation letters are sent 
by mail to home addresses. In an envelope, there are three testing-cards, instructions for 
their use, questionnaire about risk factors and an educational brochure. Invited persons are 
asked to mail testing-cards back, after they used them, together with a filled questionnaire, 
the purpose of which is to obtain information on risk factors spreading in the population 
(Draft National Program, 2007; Ministry of health, 2007).  
From the end of 2007 to the beginning of 2010, a total of 808 913 tests were distributed, of 
which only 19% were returned, 7,7% of these positive. Colonoscopy yielded 77,5% of 
pathologic findings, including 388 (5,99%) carcinomas; others were polyps (38,46%), 
hemorrhoids and diverticula (Strnad, 2010).  
8.2 How to increase screening coverage?  
One of the main problem, in mass screening programs, is how to increase the screening rates 
(coverage). This is two-sided problem. On the one side, there are problems of supply 
(program`s implementation performans), including necessary equipment, professionals, 
implement of evidence, establishment of the call-recall system, and strictly managed follow up 
(screening policy). On the other side, there is the problem of motivation of subjects from the 
target groups for screening (patients` compliance with screening). Two steps of the motivation 
process can be recognised: 1) a decision to enter the screening cycle (up-take) and a decision to 
stay in (adherence) (Flight, 2008; Smith, 2004). It is possible to affect patients` motivation (an 
internal mental process) by psychological transfer, including patients` empowerment and 
education, provided by physicians or other actors in the program (Masterson, 2006).  
8.2.1 Promotional and educational activities  
It has been recognised that the rate of up-take and adherence to screening may have a long-
term effect on screening programs effectiveness (Smith, 2004) and that both processes, 
inherent in decisions for screening, are subjected to changes, by educational and 
motivational activities (O`Neill, 2008). This is why it is important that promotional and 
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Media campaigns and promotional activities can be organised at the national or the local 
community level, initiated by policy-makers, local community authorities, or public 
health services. These activities have multifaceted aim to inform the community on: 1) risk 
factors for the most frequent cancer sites, 2) early symptoms of a disease, 3) early 
detection methods, 4) the importance of acceptance of screening (Ebling, 2006, as cited in 
Majnarić-Trtica, 2008b). More focused educational activities, oriented towards specific 
population groups, such as high-risk groups, adolescents, or workers in industry, as 
connected with occupational risk factors exposure - can be initiated and organised by non-
govermental organisations, local public health institutions, health professionals` 
associations, or cancer patients support groups (Eljuga, 2006, Ebling, 2006, as cited in 
Majnarić-Trtica, 2008b).  
Individually-oriented educational activities, for patients` groups or individuals, can be 
mostly effective if performed by primary health care workers, especially family physicians. 
In the latter case, educational activities tend to be transformed into more subjective 
cognitive tools, close to what is known as “encouragment“ and “empowerment“ of patients 
for screening. In this way, some elements of a self-decision making process, connected with 
reasoning thinking, can be tackled to change (Fig. 6) (Ackerson, 2009). In this context, it is 
important to know that there are elements of a self-decision making process that are less 
prone to change. They come from intuitive thinking, complementary to more conserved 
psyhologic structures, such as the values and attitudes.  
8.3 The role of family physicians in programs of early cancer detection  
In terms of organization, two extreme early cancer detection program forms are possible, 
either that supplied by governmental and public health institutions, or that based on the 
central role of family physicians in program`s implementation. By working at the interface 
of the health care system and the population, family physicians are in the specific position 
that enables them an opportunity to promote a vast array of preventive activities, in a pro-
active and a patient-oriented manner (Summerton, 2002). That means that the doctor 
recognises medical needs of the groups and individuals, encourages them to take 
preventive measures and manages the screening protocols, in contrast to the approach 
where the doctor generally responds to the patient`s requests. Moreover, the possibility of 
having an insight into specific characteristics of each patient, enables family physicians to 
select an appropriate way to present the preventive measures to a patient, and to create 
activities, in order to improve patient`s uptake and adherence to screening (Figure 6) 
(NHS.UK, 2011).  
There is a general assumption that prevention and early detection of cancer is insufficiently 
implemented in practice of family physicians. In most countries, family physicians are only 
partially involved, mainly through opportunistic screening (subjects are referred by a 
physician for screening outside the program supplied by public services), or only under 
certain conditions, such as rural and distant areas (Moss, 200, as cited in Majnarić-Trtica, 
2008; NHS.UK, 2011). Randomised studies in which screenings on cancer, managed by 
family physicians, were explored, are scared and not of a large-scale, to allow general 
conclusions to be drawn on (Jellema, 2010).  
 




Fig. 6. Decision stages for colorectal cancer (CRC) screening 
8.3.1 Experiences from Croatia in involving family physicians in programs of early 
cancer detection 
The leaders of the Department of Family Medicine of the Osijek University School of 
Medicine and the Health Center Osijek, have recently introduced the project “A Model of 
Early Cancer Detection Integrated in Practice of Family Physicians“, to test the idea that 
screening and early diagnosis of cancer are more efficient if integrated in practice of family 
physicians, compared to the National Program, centrally directed and supplied by the 
public services (Ebling/Project, 2007, as cited in Majnarić-Trtica, 2008b). The Project has 
started after two years of preparations and education of subjects from the target groups and 
family physicians, included in the Project, on screening and early detection methods. The 
computer program, specifically designed for keeping the records on data and for follow up 
of patients with positive screening tests, was installed into a total of twenty GP offices 
included in the Project. This program has allowed the continuous recruitment of new 
patients into the surveillance system automatically, by using personal data on sex and age 
only (Majnarić-Trtica, 2008b). Up to date, the Project has yielded its results in colorectal and 
breast cancer screening.  
8.3.1.1 The Project of early detection of colorectal cancer  
To avoid overalpping with the National Program, subjects were included in the Project for 
early detection of colorectal cancer to belong to either the 5-year lower age class (45-49) or 
the 5-year upper age class (75-79), than it is recommended according to the National 
Program (50-74). These defined target groups encompassed approximately 4 000 people, 
randomly selected from the large sample of a total of 27 000 subjects, recorded on the lists of 
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The screening protocol can be described as follows. Family physicians call the patients from 
the defined target groups by phone, deliver them letters of invitation in envelops together 
with three testing cards, brochure for their use and a questionnaire on risk factors. A 
physician also provides instructions on how to correctly apply the testing cards and other 
issues the patients may be interested in. A physician reads the applied testing cards when 
patients return them back and keeps a record on the results. Patients with positive tests are 
referred for further diagnostics by colonoscopy. A physician also keeps a record on the 
results of follow up and treatments (Pribić, 2011).  
From the beginning of April to the end of May 2009, a total number of 516 testing sets on 
occult faecal blood were delivered to patients from these two defined target groups. A high 
responding rate of 69,76% (360 cases) was recorded. This was an advantage in comparison 
with low responding rates of about 20%, obtained by the National Program. In the Project, 
there were in average 2,5% (13 cases) with positive tests, predominantely in the older age 
group, 3,5% (11 cases), compared to 1% (2 cases) recorded in the younger age group. These 
results showed that in the middle age population groups (45-49), a very low rate of positive 
tests, in systematically and non selectively performed screening on occult faecal bleeding, 
might be expected (1% positive tests). This further indicates that, for younger population 
groups, a selection of subjects at higher risk for the development of colon cancer should be 
made, prior entering the screening cycle.  
8.3.1.2 The Project of early detection of breast cancer 
The study group comprised the women from ten GP offices who have not yet been invited 
by the County Institute of Public Health to screening with mammography (Pribić, 2010). 
These women were invited during their visits for reasons other than mammography 
(opportunistic screening), or actively, by surface mail or phone. Women who did not 
respond at the first invitation, were included in the four-phased motivation program, 
carried out by a family physician and a home visiting nurse. If their decisions remaind 
unchanged after the period of three months of follow-up, they were classified as resisted the 
screening with mammography. Although a high level of responsiveness, of 80%, was 
achieved, a critical appraisal upon this study includes a suggestion for the post-hoc testing, 
to decide on whether a long-lasting and highly suggestive motivation activities are 
applicable as a routine advising procedure. In addition, results obtained here indicate, 
similar as in the case with the Project of early detection of colorectal cancer, that there is a 
need for more thoroughly prepared selection procedure, before someone starts motivating 
women to screening.  
8.3.2 Concluding remarks 
A central role of family physicians, in implementation of preventive programs, has been 
recognised as an advantage, in terms of achieving better screening coverage and 
decreasing the costs, as compared to the strictly centrally controlled programs. However, 
as with the respect to the above results - even those who advocate for this approach, must 
point out that some kind of technical and professional support to family physicians 
should be assured, to allow the program to maintain and to achieve high quality norms 
(Wender, 2007).  
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9. Current trends  
9.1 Personalised screening 
There is no doubt that the early detection of cancer is effective, but no clear attitudes on 
which strategy is more efficient than another, in a real situation within the framework of the 
current health care system organisation. Awareness has been increasing that variables such 
as “a benefit-to-risk“ and “a benefit-to-cost“ ratio, or „a quality of life measures“, should be taken 
into consideration when planning screening strategies (WHO, 2009; Aebi, 2011). New, more 
specific screening tests, such as a digital mammography, or immunochemical tests for 
testing on occult faecal bleeding, are now available and increase our chance to detect cancer 
early. However, higher prices of these tests, compared to conventional ones, require more 
specifically elaborated screening strategies, including a precise definition of who should be 
included in screening, by using which tests, and under which conditions (Jellema, 2010; 
Schousboe, JT, 2011; Warner, 2011). Evidence also suggests that variables such as the 
patient`s context, including co-morbid health disorders, and patient`s values, regarding 
specific benefits and harms from screening, are to be taken into account (Warner, 2011).  
9.2 Cancer risk prediction models 
The average risk of getting a cancer (for a 5-years, or a 10-years time period, or expressed as 
a lifetime risk) are estimated on the basis of the incidence data for the population. Many 
factors that can change these estimates to the higher or to the lower, for some of the most 
common cancers sites, have been identified (known as cancer risk factors) (US National 
Cancer Institute, 2010, 2011). Knowledge on this issue allows personalisation of risk 
assessments, based on the estimates such as the score charts, or mathematical risk prediction 
models, which can help physicians and policymakers to identify individuals who might 
benefit, more than some others, from the screening.  
Multivariable risk prediction models for some usual cancer sites have been established so 
far, based on using easily available epidemiologic and clinical data and identified risk 
factors. It has been realised, however, that the model`s precision can further be improved, if 
some biochemical or molecular biomarkers are added into the model or, more recently - 
information on a personal genome analysis (Barlow, 2006; Rosenbaum, 2010; Spitz, 2007, 
2008; Wang, 2007). Risk prediction models are expected to support a decision-making, 
beyond the traditional screening protocols, by more accurately identifying subjects of the 
target groups.  
9.3 Genetic risk estimates 
Two Mendelian genetic tests, appropriate to add value to the cancer risk assessment, have 
been established so far, including BRCA1 and BRCA2, highly penetrant breast and ovarian 
cancer predisposition genes, and a set of the mismatch repair (MMR) genes, carriers of 
which have a high risk of the most common hereditary colorectal cancer and/or 
endometrial cancer, and a lower risk of urinary tract, small intestine, ovary, gastric, 
pancreas, biliary tract and brain cancers (Balmana, 2010; 2011).  
The costs of the genetic tests were the main problem in the past, making the barriers for 
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rapidly fall down, the dominant problem is a lack of the clinical assessments of genetic risk 
estimates. For example, higher prevalence of BRCA 1/2 genes can be found in association 
with a family history of breast or ovarian cancer and a young age at onset (Balmana, 2011). 
Is there an added value of systematic testing on these genes, in women with a positive 
family history of breast cancer, beyond the standard screening with mammography, if 
familial susceptibility to breast cancer accounts for less than 25% of all breast cancer cases? 
This further arises some additional questions. Namely, carriers should advise close family 
members to obtain genetic counseling and/or testing (American Cancer Society/A manual 
Cancer and Genetics, 1997/98; Balmana, 2011). This is associated with some ethical and 
moral issues addressing both, potential carriers and physicians who provide counseling for 
them. The major concern addressing potential carriers includes living under the pressure of 
having an increased susceptibility for cancer. Concerns addressing physicians include low 
level of knowledge on variation in penetrance and expression of cancer-prone genes, and a 
lack of evidence of how a genetic counseling might have an impact on issues from the 
ethical domains (American Cancer Society/A manual Cancer and Genetics, 1997/98). 
9.4 The personalised approach in early cancer detection - the role of genomics and 
proteomics 
The rapid progress in biotechnology has been expected to provide huge benefits in 
prevention and early detection of chronic noncommunicable diseases, notably cancer, by 
implementing genomics, proteomics and other -omics techniques in practice. The main 
principle, these techniques relies on, is a possibility of identifying subjects at an early clinical 
or subclinical phase, during the course of developing a chronic disease, by obtaining the 
whole-genome sequencing (genomics), or by characterising the protein and peptide profiles 
of various biological fluids or tissues (proteomics) (Yang, 2003, Khoury, 2007, as cited in 
Majnarić-Trtica, 2009).  
These techniques have attracted the attention of both, the scientists and the public as a 
whole, in recent times, for their potential to stimulate the adoption of the personalised 
approach in medical practice, with expectancies for the improvements, equally in 
prevention, prognosis, diagnosis and treatment. For the reason that these techniques were 
developing far more rapidly than their clinical utility could be evaluated, there is no clear 
understanding yet, of what would be reasonable expectations of implementing these 
techniques in the real-life settings, and which obstacles need to be overcome. Although 
some early results of their clinical applications seem promising, such as the use of serum 
proteomics in screening for ovarian cancer, providing sensitivity of 100% and specificity of 
95% - to date, there are no visible results yet, capable to bring substantial changes into the 
standard routine (Evans, 2010; Ioannidis, 2011).  
10. Challenges for the future  
10.1 Integrated knowledge translation 
In spite of the huge advances in understanding the natural course of development of some 
common cancers, as well as in methods for their prevention and early detection, there are 
still difficulties in translating this knowledge into practice. The problem is especially 
emphasized in developing countries. Some of the main reasons include: separation between 
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public health and clinical medicine, poor coordination between the health care and science - 
on the one hand, and the health care and politics and social welfare - on the other, and the 
rapid progress in health care technology and biotechnology, leading to a rapid rise in health 
care costs and the disparity in access. In addition, there is a need for better integration of the 
new, individually-oriented approaches into the established early detection programs 
(Evans, 2010; Hudson, 2011; Majnarić-Trtica, 2009; Pigeot, 2010).  
There are initiatives to bridge these gaps, by favouring a collective approach to problems 
and questions concerning health. It is believed that this might be achieved through a 
leadership shift (from a traditionally top-down to a coalition leadership between 
practitionars and researchers/scientists), and the process of integration of the knowledge 
bases, among multiple health care and other social sectors. Namely, an awareness is 
growing up that the issues of public health are intimately embedded in the 
socioenvironmental context and should be managed within this context. For this reason, 
researches, public health professionals and policy decision-makers, should collaborate in 
searching for “better“, “faster“ and “cheaper“ interventions, aimed at improving the health 
in the community. The development of the common information and communication 
technology infrastructure are expected to facilitate these common initiatives (Lapaige, 2010; 
majnarić-Trtica, 2009; Patridge, 2011).  
10.2 The chronic care model  
Improvements in the early detection, diagnosis and treatment of cancer enable people with 
cancer living longer and managing their cancers as a chronic illnesses. This consideres a 
long-term surveillance, including prevention, early detection, diagnosis, treatment, care 
after the treatment, and survivorship. Demands are put on patients and their families, in 
managing care on their own, and on family physicians, in providing them education and 
support, as well as a follow up (McCorkie, 2011).  
11. Conclusions 
Experiences gathered up-to-date show that the programs for early cancer detection are best 
performed if well organised and coordinated, independently on whether they are conducted 
by governmental and public health institutiones, or predominantly supplied by family 
medicine teams. In highly income countries, with long tradition in organising early cancer 
detection programs, expected curing and survival rates have been achieved. These 
favourable results can not be attributed only to a large number of professionals employed, 
good technical facilities and government officials coordinating the programs, but, even 
partially, to the comprehensively performed and sustainable driven strategies aimed at 
cutting the common risks factors burden for the most important chronic diseases, including 
cardiovascular diseases, diabetes and cancer. In this sense, the best way to invest in 
populations` health, would be by ensuring health protective working and living 
environment (Cancer Society of Finland, 2011; WHO/Health 2020, 2011). In case of lower 
income countries, strong orientation towards primary health care in performing programs 
of prevention and early detection of cancer, could be the best solution, as it has been proved 
that better primary care resources considerable contribute to reducing the adverse impact of 
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depends on good primary health care (system), that means that primary care is reflective of 
a specific health care system policy. This reasoning was in the background of the recent 
iniciative of the European Member States, to potentiate a wave of health reforms across 
Europe (WHO/Health 2020, 2011).  
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1. Introduction 
Abnormal uterine peri- and postmenopausal bleeding represent more than two thirds of the 
Gynecological consultations and the primary exclusion target off such presentations would 
be endometrial cancer.(1)Endometrial cancer is the most common malignancy of the female 
genital tract in the world and the seventh most common cause of death from cancer in 
women in western Europe.(2)The disease thus motivates the development of adequate 
prognostic determinants for more accurate triage of patients through various treatment 
modalities and to provide better insight into the cell biology of the disease.In recent years, 
certain factors have led to an increasing awareness of and emphasis on diagnosis and 
treatment of endometrial cancer. These factors include the declining incidence of cervical 
cancer and related deaths in the United States, prolonged life expectancy, postmenopausal 
use of hormone replacement therapy, and earlier diagnosis. Moreover, the availability of 
easily applied diagnostic tools and a clearer understanding of premalignant lesions of the 
endometrium have led to an increase in the number of women diagnosed with endometrial 
cancer.(3)Screening for the disease and thus its prediction is highly recommended, however , 
there is overlap between the terms prediction and forecast, as prediction implies that some 
outcome is expected, while a forecast may cover a range of possible outcomes.(4) 
2. Risk factors(5) 
- Associated with increased risk: 
Obesity, Menopausal estrogen use, Diabetes mellitus, Nulliparity, Hypertension, Late 
menopause, Early menarche (<12 yrs), Polycystic ovarian syndrome, and Gall bladder 
disease. 
- Associated with decreased risk: Smoking & Oral contraceptives 
3. Presentation 
Most cases of endometrial cancer are diagnosed in early stages because of abnormal uterine 
bleeding as the presenting symptom in 90% of the cases. (6) It is still debatable, which 
diagnostic tool is best performing for patients with postmenopausal bleeding. Hysteroscopy 
and/or hysteroscopic guided endometrial biopsies as well as endometrial sampling tools 
almost exclusively replaced the older modalities for investigating such cancer such as 
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bleeding as the presenting symptom in 90% of the cases. (6) It is still debatable, which 
diagnostic tool is best performing for patients with postmenopausal bleeding. Hysteroscopy 
and/or hysteroscopic guided endometrial biopsies as well as endometrial sampling tools 
almost exclusively replaced the older modalities for investigating such cancer such as 
dilatation and curettage (D&C).(7) 
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The Pap test helped somehow in the past through incidental detection of some early cases with 
endometrial cancer, however, the test was proven to be of too low sensitivity and positive 
predictive value in terms of detecting both cervical and endometrial cancers.(8)It must be 
remembered that screening refers to the evaluation of the asymptomatic patient. When 
bleeding occurs, evaluation becomes diagnostic rather than screening. A history of bleeding or 
demonstrated radiographic evidence of endometrial pathology removes a patient from the 
realm of screening and demands investigation, i.e., an endometrial biopsy.(9) 
While screening for endometrial cancer has been evaluated in prospective studies, the 
efficacy of endometrial screening has never been evaluated in a large prospective 
randomized controlled trial.Endometrial biopsy is easily performed as an office procedure 
and has good sensitivity, with the small number of false negatives most likely a result of 
sampling error. Transvaginal ultrasound (TVU) has also been used as a noninvasive 
screening test to evaluate the endometrium.(9) 
4. Diagnosis 
4.1. Screening of asymptomatic cases for early detection 
High index of suspicion must be maintained if endometrial carcinoma will be diagnosed at 
an early stage. Postmenopausal bleeding should be taken to mean endometrial carcinoma 
until proved otherwise.(10) 
1. Transvaginal sonography (TVS): is used to assess the endometrial thickness. This has 
been used as screening method combined with outpatient suction endometrial 
sampling (e.g. using a pipette). The cutoff thickness (myometrium to myometrium) 
expected in postmenopausal women, was once thought to be up to 8 mm.(11) If the 
endometrium is thickened or insufficient material is obtained by biopsy for diagnosis, 
then a more invasive procedure is required. This ideally comprises hysteroscopy 
accompanied or followed by a diagnostic curettage.(11)However, as yet, there is no 
agreed-upon criterion for endometrial thickness that has both a high sensitivity and 
specificity; a high rate of false-positive results is also a limiting factor.(12) 
Previous meta-analyses on endometrial thickness measurement probably have 
overestimated its diagnostic accuracy in the detection of endometrial carcinoma. We advise 
the use of cutoff level of 3 mm for exclusion of endometrial carcinoma in women with 
postmenopausal bleeding.(13) 
TVS has the added advantage of detecting any ovarian lesion and assessing the extent of 
myometrial involvement of endometrial cancer which can be achieved as efficient as 
Magnetic resonance imaging (MRI) utilization for the same purpose.(14) 
2. Progesterone challenge test (PCT): 
It is a reliable, non-invasive test to determine if estrogens, either endogenous or exogenous, 
are present in sufficient quantity to cause endometrial proliferation. Postmenopausal 
women with intact uterus should be given 100 milligrams of progesterone intramuscularly, 
if withdrawal bleeding follows, this indicates high endogenous estrogen priming the 
endometrium denoting a high risk patient. On the other hand, negative PCT i.e. no 
withdrawal bleeding, indicates low endogenous estrogen and consequently low risk patient. 
The test should be repeated on annual basis for those patients. (15) 
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3. Endometrial sampling: 
Cytological study: to detect exfoliated malignant endometrial cells by a cervicovaginal smear 
or jet lavage aspiration. It, unfortunately, gives less reliable results than expected with a 
sensitivity of not more than 50%. (16) 
Endometrial tissue biopsy: Accepted as a first step in evaluating a high-risk patient for 
endometrial carcinoma, with a diagnostic accuracy of 90 – 98%. 
The endometrial tissue biopsy can be obtained using: 
- Vacuum aspiration: using Carman’s cannula which is 3-4mm diameter suction curette 
with 300-600 mm Hg negative pressure. 
- Intrauterine brushing: using a metallic wire with nylon bristles rotated all over the 
uterine cavity. 
- Novak or Randall curette: office procedure, without anesthesia, where scrapes are taken 
from each uterine wall and sent for histopathological examination.(17) 
4.2. Diagnosis of symptomatic cases with postmenopausal uterine bleeding 
Diagnostic curettage has been the standard means for the diagnosis of endometrial pathology. 
The naked-eye picture can be suggestive of malignancy if the curettings are profuse, in the 
form of cheesy lumps rather than strips and if they are dark in color. Failure of the uterine 
wall to "grate" with curetting is suggestive. However, histopathological confirmation should 
be-awaited.(18) 
Fractional curettage (samples taken from the endocervix then from the endometrial cavity) can 
also be used to diagnose or exclude cervical involvement and thus for clinical staging. (19) 
Hysteroscopy can be used in the diagnosis of endometrial carcinoma. Because 15-20% of the 
uterine cavity with possible malignant growth could be missed in conventional curettage, 
hysetroscope allows inspecting the endometrial cavity and indicating the site from which 
endometrial biopsy is to be taken under vision.(20) 
4.3. Genetic analysis 
Genetic testing for mutations in the mismatch repair genes is available, and if a pathogenic 
change is found within a family, predictive testing becomes available for unaffected family 
members to assess microsatellite instability, a feature of mismatch repair genes mutation.(21) 
On the other hand, immunohistochemical staining for p53 gene demonstrating 
overexpression of p53.(22) 
Final diagnosis for pretreatment assessment and staging must entail: 
Radiological imaging: 
- Computer axial tomography (CT) scan with contrast can be helpful in pretreatment 
staging by identifying the depth of myometrial invasion, abdominal lymph node 
involvement, spread to pelvic and extra-pelvic organs, and ureteric invasion. (23) 
- Magnetic resonance imaging (MRI) is a more advanced diagnostic tool in pretreatment 
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- Intravenous urography (IVU) to check for ureteric involvement. 
- Plain X-ray chest to detect lung secondaries in advanced stage of the disease. 
- Radioisotope scan to detect distant metastasis and bone deposits. 
- Lymphangiography: for lymph node involvement for preoperative staging; it is now, 
however, replaced by CT scan.(18) 
- Endoscopy: (in advanced cases) 
- Cystoscopy: to detect bladder infiltration. 
- Sigmoidoscopy: to check for rectal and sigmoid colon infiltration.(18) 
4.4. Biochemical markers related to endometrial carcinoma: 
Gynecologists happen to experience that patients with tumors that are identical in grade and 
stage often have significantly different clinical outcomes or responses to therapy. In order to 
identify an objective biological factor correlating with tumor aggressiveness, many tumor 
markers have been investigated. So far, CA125 is one of the most reliable tumor marker for 
adenocarcinoma of the uterus and frequently used in a clinical setting. Elevated CA-125 
levels have also been observed in serum, menstrual effluent, and the peritoneal fluid of 
women with endometrial carcinoma.(25)It can be assumed that if a patient with endometrial 
cancer had an elevated preoperative CA 125, it would probably be a cancer with poor 
prognosis. Thus, CA 125 is considered a positive marker in these cases and its high 
production is associated with increased metastatic potential. In addition, CA 125 levels were 
found to be independent risk factor for pelvic lymph node metastasis.(26, 27) 
Not only in the sera of patients with endometrial carcinoma, do CA 125 levels  
rise significantly, but also in their tissues. Cancer tissues contain CA 125 and the percentage 
of positive CA 125 tissue staining is significantly higher than that of elevated CA 125  
serum levels. An increase in serum CA125 after operation predicted the possibility of 
recurrence. (28, 29) 
The potent cytokine; tumor necrosis factor alpha (TNF-α) was first identified to be 
synthesized and secreted by the human endometrium. The endometrial epithelial cells are a 
major source of TNF-α. TNF-α may be useful in the discrimination of malignant from 
benign gynecological diseases and in monitoring tumor activity in patients early in the 
malignancy process. (30, 31, 32) 
Tumor necrosis factor alpha (TNF α) concentration was determined by a solid phase 
immunoradiometric assay. The rate of abnormally high values of serum TNF α increased 
with advancing stage of the disease. On the other hand, serum TNF α level in cases of 
endometrial hyperplasia was significantly lower than in healthy individuals. It seems that 
the rise of serum TNF α in cases of endometrial carcinoma represents a possible mechanism 
of immune surveillance. It is thus suggested that serum TNF α estimations for the 
differential diagnosis of benign and malignant lesions of the endometrium in women with 
postmenopausal bleeding could be beneficial. (33) 
4.5. Prognostic factors(19) 
Multiple factors have been identified which significantly influence the prognosis in 
endometrial carcinoma; some of these factors are interdependent: 
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Prognostic factors in endometrial carcinoma: 
1. Age and body morphology. 
2. Stage. 
3. Histopathologic type. 
4. Histologic differentiation. 
5. Depth of myometrial invasion. 
6. Lymph node involvement. 
7. Peritoneal cytology. 
8. Steroid receptor status 
9. DNA ploidy. 
10. Molecular indices. 
1. Age and body morphology: 
Older patients do worse. Obese patients do better than lean ones. It seems that the obese, 
hyperlipidemic women, with evidence of unopposed estrogen exposure like anovulatory 
uterine bleeding, infertility, late menopause, and hyperplasia of ovarian stroma tend to have 
more differentiated endometrial carcinoma with better prognosis. 
2. Stage: 
Involvement of the cervix definitely worsens the prognosis; cervical stromal invasion  
is worse than involvement of the endocervix only. The overall survival rate for  
endometrial cancer is high as there is a preponderance of women diagnosed with stage I 
disease. 
3. Histological type: 
The rare tumor types of endometrial carcinoma like serous papillary, clear cell and 
squamous carcinoma have a definitely poorer prognosis than usual enometrioid 
adenocarcinoma. The frequent presence of squamous metaplasia not showing malignant 
feature i.e. adenoacanthoma, does not change the prognosis. 
4. Histological differentiation: Tumor grade: 
As the tumor gets less differentiated, the risk of deep myometrial invasion increases. Within 
each stage the prognosis is therefore, influenced by the tumor grade. 
5. Depth of myometrial invasion: 
Deep invasion is associated with higher rates of lymph node involvement and is usually 
associated with lesser degrees of differentiation. Reaching the serosa will shift the disease to 
stage III and is associated with poor prognosis. 
6. Lymph node involvement: 
There is a good deal of correlation between lymph node involvement and other prognostic 
factors. In stage I disease, the incidence of pelvic lymph node involvement is about 10 % and 
the 5-years survival in these subset is only 30% as compared with more than 70% for the 
whole of stage I cases. (34) 
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- Intravenous urography (IVU) to check for ureteric involvement. 
- Plain X-ray chest to detect lung secondaries in advanced stage of the disease. 
- Radioisotope scan to detect distant metastasis and bone deposits. 
- Lymphangiography: for lymph node involvement for preoperative staging; it is now, 
however, replaced by CT scan.(18) 
- Endoscopy: (in advanced cases) 
- Cystoscopy: to detect bladder infiltration. 
- Sigmoidoscopy: to check for rectal and sigmoid colon infiltration.(18) 
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serum levels. An increase in serum CA125 after operation predicted the possibility of 
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with advancing stage of the disease. On the other hand, serum TNF α level in cases of 
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the rise of serum TNF α in cases of endometrial carcinoma represents a possible mechanism 
of immune surveillance. It is thus suggested that serum TNF α estimations for the 
differential diagnosis of benign and malignant lesions of the endometrium in women with 
postmenopausal bleeding could be beneficial. (33) 
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Multiple factors have been identified which significantly influence the prognosis in 
endometrial carcinoma; some of these factors are interdependent: 
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1. Age and body morphology: 
Older patients do worse. Obese patients do better than lean ones. It seems that the obese, 
hyperlipidemic women, with evidence of unopposed estrogen exposure like anovulatory 
uterine bleeding, infertility, late menopause, and hyperplasia of ovarian stroma tend to have 
more differentiated endometrial carcinoma with better prognosis. 
2. Stage: 
Involvement of the cervix definitely worsens the prognosis; cervical stromal invasion  
is worse than involvement of the endocervix only. The overall survival rate for  
endometrial cancer is high as there is a preponderance of women diagnosed with stage I 
disease. 
3. Histological type: 
The rare tumor types of endometrial carcinoma like serous papillary, clear cell and 
squamous carcinoma have a definitely poorer prognosis than usual enometrioid 
adenocarcinoma. The frequent presence of squamous metaplasia not showing malignant 
feature i.e. adenoacanthoma, does not change the prognosis. 
4. Histological differentiation: Tumor grade: 
As the tumor gets less differentiated, the risk of deep myometrial invasion increases. Within 
each stage the prognosis is therefore, influenced by the tumor grade. 
5. Depth of myometrial invasion: 
Deep invasion is associated with higher rates of lymph node involvement and is usually 
associated with lesser degrees of differentiation. Reaching the serosa will shift the disease to 
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6. Lymph node involvement: 
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the 5-years survival in these subset is only 30% as compared with more than 70% for the 
whole of stage I cases. (34) 
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7. Peritoneal cytology: 
Obtaining peritoneal washings for cytology examination is an easy procedure for 
assessment of prognosis. However, its value independent of other prognostic indicators is 
not fully established. (35) 
8. Hormone (steroid) receptor status:  
Estrogen receptor and progesterone receptor levels have been shown to be prognostic 
indicators for endometrial cancers independent of grade. Patients with tumors positive for 
one or both receptors have longer survival than patients whose carcinomas lack the 
corresponding receptors. Even patients with metastasis have an improved prognosis with 
receptor positive tumors. Progesterone receptor levels appear to be stronger predictors of 
survival than estrogen receptor levels, and the higher the absolute level of the receptor, the 
better the prognosis. (36) 
9. DNA ploidy and proliferative index: 
Flow cytometry has been used in assessment of the ploidy of the tumor. This determines 
cellular nuclear DNA content and measures the fraction of the tumor cells in proliferative 
phase (S- phase). Flow cytometry will determine DNA histogram, which reflects the cell 
cycle phase. G0 and G1 cells contain diploid nuclear DNA content. In a well-differentiated 
tumor, a smaller number of cells enter the S-phase and begin DNA replication (S-phase 
fraction). DNA ploidy can be denoted as DNA index (DI), which is the numerical ratio of 
DNA content of the tumor cells to the DNA content of G0/G1 peak of normal control 
population. A diploid tumor has a DI range of 0.95 % to 1.1 and a tetraploid tumor has a DI 
range of 1.9 to 2%; peaks outside these ranges e.g. 1.5 or 2.6 are defined as aneuploid. Most 
endometrial cancers are diploid but aneuploidy indicates advanced disease and a poor 
prognosis. A raised fraction of cells in the S-phase (with DI around 2) also indicates a poor 
prognosis. 
10. Genetic and molecular markers: 
Analysis of the mutations in mismatch repair (MMR) genes can be achieved through 
studying blood samples or tumor blocks to assess microsatellite instability, a feature of 
mismatch repair gene mutations. These mutations have been reported in 10% to 20% of 
endometrial adenocarcinomas. Alteration of the tumor suppressor gene p53 has also been 
demonstrated in about 20% of endometrial carcinomas and has been associated with 
papillary serous cell type, advanced stage and poor prognosis. (37,38) 
In summary, endometrial cancer screening, and thus its outcome prediction (forecast) seem 
to be achievable in a more variety of ways than any other female genital malignancy. Early 
detection is definitely the first step to attain a complete cure. The management options for 
endometrial cancer, and thus the survival rate from the disease would depend largely on 
early detection modalities mentioned above. The following are some recommendations from 
the American cancer Society (ACS) for early detection of the disease based on patients' 
characteristics.(9)Recommendations for Women at Average Risk: There is no indication that 
screening for endometrial cancer is warranted for women who have no identified risk 
factors.(39) 
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Recommendations for Women at Increased Risk: There is no indication that screening for 
endometrial cancer should be recommended for women at increased risk for endometrial 
cancer because of history of unopposed estrogen therapy, late menopause, tamoxifen 
therapy, nulliparity, infertility or failure to ovulate, obesity, diabetes, or hypertension.(39) 
Recommendations for Women at High Risk: The American Cancer Society recommends that 
annual screening for endometrial cancer with endometrial biopsy should be offered by age 
35 for women with or at risk for hereditary nonpolyposis colorectal cancer (HNPCC). 
Women in this high-risk group should be informed about the risks and symptoms of 
endometrial cancer, and should be informed about potential benefits, risks, and limitations 
of testing for early endometrial cancer detection. 
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Obtaining peritoneal washings for cytology examination is an easy procedure for 
assessment of prognosis. However, its value independent of other prognostic indicators is 
not fully established. (35) 
8. Hormone (steroid) receptor status:  
Estrogen receptor and progesterone receptor levels have been shown to be prognostic 
indicators for endometrial cancers independent of grade. Patients with tumors positive for 
one or both receptors have longer survival than patients whose carcinomas lack the 
corresponding receptors. Even patients with metastasis have an improved prognosis with 
receptor positive tumors. Progesterone receptor levels appear to be stronger predictors of 
survival than estrogen receptor levels, and the higher the absolute level of the receptor, the 
better the prognosis. (36) 
9. DNA ploidy and proliferative index: 
Flow cytometry has been used in assessment of the ploidy of the tumor. This determines 
cellular nuclear DNA content and measures the fraction of the tumor cells in proliferative 
phase (S- phase). Flow cytometry will determine DNA histogram, which reflects the cell 
cycle phase. G0 and G1 cells contain diploid nuclear DNA content. In a well-differentiated 
tumor, a smaller number of cells enter the S-phase and begin DNA replication (S-phase 
fraction). DNA ploidy can be denoted as DNA index (DI), which is the numerical ratio of 
DNA content of the tumor cells to the DNA content of G0/G1 peak of normal control 
population. A diploid tumor has a DI range of 0.95 % to 1.1 and a tetraploid tumor has a DI 
range of 1.9 to 2%; peaks outside these ranges e.g. 1.5 or 2.6 are defined as aneuploid. Most 
endometrial cancers are diploid but aneuploidy indicates advanced disease and a poor 
prognosis. A raised fraction of cells in the S-phase (with DI around 2) also indicates a poor 
prognosis. 
10. Genetic and molecular markers: 
Analysis of the mutations in mismatch repair (MMR) genes can be achieved through 
studying blood samples or tumor blocks to assess microsatellite instability, a feature of 
mismatch repair gene mutations. These mutations have been reported in 10% to 20% of 
endometrial adenocarcinomas. Alteration of the tumor suppressor gene p53 has also been 
demonstrated in about 20% of endometrial carcinomas and has been associated with 
papillary serous cell type, advanced stage and poor prognosis. (37,38) 
In summary, endometrial cancer screening, and thus its outcome prediction (forecast) seem 
to be achievable in a more variety of ways than any other female genital malignancy. Early 
detection is definitely the first step to attain a complete cure. The management options for 
endometrial cancer, and thus the survival rate from the disease would depend largely on 
early detection modalities mentioned above. The following are some recommendations from 
the American cancer Society (ACS) for early detection of the disease based on patients' 
characteristics.(9)Recommendations for Women at Average Risk: There is no indication that 
screening for endometrial cancer is warranted for women who have no identified risk 
factors.(39) 
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Recommendations for Women at Increased Risk: There is no indication that screening for 
endometrial cancer should be recommended for women at increased risk for endometrial 
cancer because of history of unopposed estrogen therapy, late menopause, tamoxifen 
therapy, nulliparity, infertility or failure to ovulate, obesity, diabetes, or hypertension.(39) 
Recommendations for Women at High Risk: The American Cancer Society recommends that 
annual screening for endometrial cancer with endometrial biopsy should be offered by age 
35 for women with or at risk for hereditary nonpolyposis colorectal cancer (HNPCC). 
Women in this high-risk group should be informed about the risks and symptoms of 
endometrial cancer, and should be informed about potential benefits, risks, and limitations 
of testing for early endometrial cancer detection. 
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1. Introduction 
Increasing the effectiveness of current chemotherapy strategies requires a higher dosage, the 
greater duration of treatment, multiple chemotherapy cycles, and strong adherence to 
recommended interval lengths between cycles. Anticancer drug administration (usually 
intravenously) may result in vessel wall irritation, phlebitis/phlebothrombosis, and tissue 
necrosis due to accidental drug extravasation. The small diameter of a peripheral vein, low 
blood flow velocity, easy bacterial invasion due to the proximity of the blood vessel to the 
contaminated skin frequently and quickly result in the aforementioned complications which 
render peripheral veins impossible to use as a venous access. A central venous access allows 
physicians to avoid most of these problems. However, its use may also lead to complications 
including infection, thrombosis and aeroembolism. Apart from that, multiple blood vessel 
punctures and a central vein catheterization for diagnostic tests, chemotherapy, 
maintenance treatment, and intravenous feeding have a negative effect on the quality of life. 
It should also be kept in mind that in pediatrics such an intrusive diagnostic method is done 
under general anesthesia, which is hazardous, by itself. Since a cancer treatment lasts for 
many months and even years, patients with traditional subclavian catheters face a 
significant decrease in quality of life, and experience difficulties in providing personal 
hygiene. This results in serious complications, the most dangerous of them being a catheter-
related infection and a catheter sepsis. They are often caused by a slight shift in a catheter 
position, which allows the pus from the puncture wound to enter the patient’s bloodstream 
along the outer wall of the catheter. Children may quite frequently put themselves in danger 
by removing an external catheter while receiving chemotherapy. It is especially dangerous if 
it occurs within the period of pancytopenia when the low blood count eliminates the option 
of a subclavian catheter, and thus an adjunctive therapy has to be given via a peripheral 
venous access. All the abovementioned issues may postpone the next treatment stage and 
ultimately have a negative effect on the whole treatment strategy and decrease its 
effectiveness. 
Thus, the use of a totally implantable venous access system (portacath) is preferable. It is 
unaffected by external factors when it is not used for infusion, it is comfortable, provides a 
high quality of life, and is installed once lasting for the whole therapy period.  
 
Cancer Management 54
[39]  Kim YB, Ghosh K, Ainbinder S, Berek JS. Diagnostic and therapeutic advances in 
gynecologic oncology: screening for gynecologic cancer. Cancer Treat Res 1998; 95: 
253–276.  
4 
Long-Term Venous Access in Oncology: 
Chemotherapy Strategies, Prevention and  
Treatment of Complications 
Rykov Maxim and Buydenok Yury 
Institute of Pediatric Oncology and Hematology,  
N. N. Blokhin Cancer Research Center, Moscow, 
Russia 
1. Introduction 
Increasing the effectiveness of current chemotherapy strategies requires a higher dosage, the 
greater duration of treatment, multiple chemotherapy cycles, and strong adherence to 
recommended interval lengths between cycles. Anticancer drug administration (usually 
intravenously) may result in vessel wall irritation, phlebitis/phlebothrombosis, and tissue 
necrosis due to accidental drug extravasation. The small diameter of a peripheral vein, low 
blood flow velocity, easy bacterial invasion due to the proximity of the blood vessel to the 
contaminated skin frequently and quickly result in the aforementioned complications which 
render peripheral veins impossible to use as a venous access. A central venous access allows 
physicians to avoid most of these problems. However, its use may also lead to complications 
including infection, thrombosis and aeroembolism. Apart from that, multiple blood vessel 
punctures and a central vein catheterization for diagnostic tests, chemotherapy, 
maintenance treatment, and intravenous feeding have a negative effect on the quality of life. 
It should also be kept in mind that in pediatrics such an intrusive diagnostic method is done 
under general anesthesia, which is hazardous, by itself. Since a cancer treatment lasts for 
many months and even years, patients with traditional subclavian catheters face a 
significant decrease in quality of life, and experience difficulties in providing personal 
hygiene. This results in serious complications, the most dangerous of them being a catheter-
related infection and a catheter sepsis. They are often caused by a slight shift in a catheter 
position, which allows the pus from the puncture wound to enter the patient’s bloodstream 
along the outer wall of the catheter. Children may quite frequently put themselves in danger 
by removing an external catheter while receiving chemotherapy. It is especially dangerous if 
it occurs within the period of pancytopenia when the low blood count eliminates the option 
of a subclavian catheter, and thus an adjunctive therapy has to be given via a peripheral 
venous access. All the abovementioned issues may postpone the next treatment stage and 
ultimately have a negative effect on the whole treatment strategy and decrease its 
effectiveness. 
Thus, the use of a totally implantable venous access system (portacath) is preferable. It is 
unaffected by external factors when it is not used for infusion, it is comfortable, provides a 





2. Materials and methods 
Since 2000, more than 1500 oncological patients (aged from 6 months to 87 years) of the N.N. 
Blokhin Cancer Research Center have had a totally implantable venous access system 
installed subcutaneously.  
A port is a reservoir compartment made of metal (titanium) or plastic (polysulphone). The 
base of a port has a device securing it in a fixed position, while the upper part contains a 
silicone septum, which can be punctured multiple times with a special needle for drawing 
blood, drug administration, and flushing the device. A catheter is attached to the side of the 
port with the distal end of the former located in the central vein. A dual chamber port is 
used when the current treatment strategies require simultaneous administration of 
incompatible drugs.  
A port implantation requires a sterile environment, and that is why it is performed in an 
operating room. It is done under local anesthesia in adults and general anesthesia in 
children. The port can also be used for preoperative management.  
Successful venous access system implantation requires an ultrasound-guided 
transcutaneous catheterization of the superior vena cava via an external jugular, internal 
jugular or subclavian vein (using a subclavicular or supraclavicular approach). An access to 
the superior vena cava via an internal jugular or subclavian vein (with a supraclavicular 
approach) is preferred to an easier traditional subclavicular approach to the subclavian vein. 
The latter option is undesirable, for the catheter may get lodged between the first rib and the 
clavicle and eventually rupture leading to drug extravasation. Another problem is 
connected with possibility that the catheter can be torn off. 
It should be noted that an adjacent artery injury may occur during venipuncture, in which 
case pulsing bright red blood enters the vein under great pressure resulting in a hematoma 
formation and its infection. This decreases the odds of success when attempting to gain a 
venous access from the chosen venipuncture site.  
The central vein catheterization in the neck area may also lead to an accidental puncture and 
trauma of thoracic duct, nerve plexus, phrenic, vagus and recurrent nerve, esophagus, 
larynx and trachea. Gaining a central venous access in the clavicle area bears the risk of an 
accidental puncture and trauma of subclavian artery, pleural cavity, lung and brachial 
plexus. In case of thoracic duct puncture (a rare complication of attempting to gain left-sided 
venous access) the catheter gets filled with milk colored fluid – lymph. The needle should be 
instantly removed and adequate pressure applied for 5 – 10 minutes to avoid formation of a 
hematoma. The subsequent venous access has to be located on the other side or as far as 
possible from the previous one. 
A nerve plexus trauma is characterized by neurological symptoms and acute pain 
reminiscent of an electric shock. This complication also requires immediate needle 
withdrawal.  
In case of an airway puncture and a lung tissue trauma, air appears in the syringe. However, 
this may be also due to loose connection of the syringe with the needle. As a result 
crepitation can be heard upon neck and thorax palpation and the patient complains of 
shortness of breath and chest pain caused by an increasing pneumothorax. In some patients, 
pneumothorax is asymptomatic and is diagnosed by thorough auscultation and X-ray 
examination. The outcome depends on the rate of the pneumothorax progression, its 
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severity and swift conversion of a closed pneumothorax to an open one by means of 
thoracostomy. Each central vein catheterization should be followed by chest x-ray. This 
allows to verify the position of the catheter and to assess the cardiovascular system. 
In order to avoid the aforementioned complications a venipuncture should be performed 
under ultrasound control.  
Successful use of an implantable venous access system is only possible when the distal end of 
the catheter is situated in the superior vena cava above its opening into the right atrium. The 
position of the catheter in the superior vena cava is most accurately determined by X-ray 
visualization in a cath lab or general operating room equipped with an electron-optical image 
intensifier. These methods are preferable in pediatric oncology for small vein diameter makes 
it quite hard to drive the guidewire precisely into the superior vena cava and avoid its entry 
into cervical veins. Accurate catheter position monitoring can also be achieved with the help of 
an endocardial electrogram. However, we recommend against using this method in children. 
Following the catheter implantation a 2 – 4 cm incision is done below the puncture site. The 
length of the incision depends on the port chamber size. A special subcutaneous recess (or 
pocket) is made below the incision and a subcutaneous tunnel is formed using a tunneler, 
which is included in the implantable port kit. Afterwards the catheter is led through the 
subcutaneous tunnel into the port chamber with the help of a tunneler. Then the port 
chamber is inserted into the subcutaneous recess and fixed with interrupted sutures to the 
adjacent tissues and the incision is closed layer by layer. Throughout the implantation 
drawing some blood from the catheter or the port with a Huber needle constantly checks 
procedure the position of the catheter and the port. The port is ready for the infusion several 
hours after implantation. 
The steps of the surgery are listed below: 
1. Internal jugular vein ultrasound mapping; 
2. Internal jugular vein puncture; 
3. Guidewire insertion with radioscopic monitoring and needle removal; 
4. Dilator (bougie) insertion over the guidewire; 
5. Guidewire removal from the catheter and clamping of the latter to avoid hemorrhage 
and aeroembolism; 
6. Catheter insertion into the dilator filled with normal saline; 
7. Blood withdrawal and immediate catheter flushing for prevention of thrombosis; 
8. Skin incision in the subclavian area below the puncture site; 
9. Subcutaneous pocket formation below the incision; 
10. Dilator removal (splitting); 
11. Subcutaneous tunnel formation which links the skin pocket to the puncture site; 
12. Catheter tunneling from the puncture site to the skin pocket and positioning in the 
superior vena cava under X-ray monitoring; 
13. Additional blood withdrawal and catheter flushing; 
14. Ligature appliance in the skin pocket and port chamber fixation; 
15. Port chamber and catheter connection, and fixing it in place with a special lock; 
16. Port insertion into the skin pocket and ligation;  
17. Layer by layer incision closure above the port; 
18. Blood withdrawal from the port chamber with a Huber needle and thorough flushing 
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The port puncture should only be done with a special Huber needle whose tip is designed to 
rule out the possibility of the silicon septum damage. The retrograde blood flow from the 
venous port upon slight aspiration is indicative of the proper infusion system functioning. 
Unlike regular needles, a Huber needle does not cut the silicone port septum, “spreading” it 
instead and keeping the system airtight for several years. The port puncture is a simple 
procedure, while the infusion system management requires trained staff. The port puncture 
can be repeated up to 2000 times provided it is performed with Huber needles which in 
theory allow using the system weekly for 40 years. 
A visual check is needed prior to the needle insertion. If no signs of inflammation are 
present, the exact location of the septum is determined by palpation. Afterward while the 
port is kept in place between the index finger and the thumb, the needle is inserted 
vertically through the skin and the septum until it reaches the posterior wall of the port 
chamber. When accessing the port, the sterility should be ensured that implies the use of 
sterile gloves when performing the puncture. Modern antiseptics should be used for skin 
disinfection above the port and the puncture needle should be covered with disposable 
sterile dressing. Long presence of bacterial growth facilitating media (blood, proteins, amino 
acids, carbohydrates) in the port chamber and use of solutions from previously opened 
bottles (this especially concerns heparin) should be avoided. If needle insertion is successful, 
blood is drawn into the syringe upon careful aspiration. The blood (1 – 2 ml) should be 
disposed of and the port should be immediately flushed with 20.0 ml of normal saline. 10 ml 
or bigger syringes are needed in order to prevent catheter disconnection from the port 
chamber by excessive pressure. An incorrect insertion of the needle into the port may lead to 
extravasation and a fluid bleb formation in the port area. 
After the infusion is complete and the needle is removed the patient can resume his normal 
life, bathe and even go swimming.  
There are three main complications, which can pose a problem for prolonged central venous 
access use – thrombophlebitis at the site of the central venous catheter implantation, catheter 
thrombosis, and infusion system contamination with consequent infection. 
The first complication is characterized by an edema, cyanosis and sometimes the 
hyperthermia of the upper limb and neck at the site of the venous access. Thrombophlebitis 
spread and progression rate is monitored with ultrasound. Chest X-ray and bacteriological 
study of the intravenous fluid in the catheter and port are highly recommended. The port 
should be removed if clinical situation allows it. In some cases it can be left in place 
provided the anticoagulant therapy is given promptly and contraindications are absent.  
Catheter thrombosis is most likely to occur due to the venous access system 
mismanagement when the medical staff fails to flush the port after blood withdrawal or 
infusion. The preferred drug for the port flushing is urokinase – a fibrinolytic agent that 
activates glu-plasminogen and lys-plasminogen and converts them into plasmin, which 
causes enzymatic breakdown of fibrin. Fibrin mesh breakdown leads to clot disintegration 
and fragmentation. Clot fragments are then carried off with the blood flow or dissolved in 
situ. 2 – 2.5 ml of urokinase should be introduced into the system with exposure time of 15 
minutes, followed by its aspiration from the portacath. 
The infusion system contamination is a very dangerous condition that poses a threat of 
generalized sepsis. The first and rather reliable sign of the portacath contamination is high 
fever and algor developing 30 minutes after the introduction of normal saline into the port. 
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Contamination usually occurs in the infusion system inner environment and the implantation 
site may show no local signs even if the portacath is left unused. However, inflammation 
signs, often accompanied by thrombophlebitis, may be present at the site of the venous access 
system. The diagnosis can be verified with a bacteriological study of the fluid present in the 
infusion system and if it is, the venous access system has to be removed. The main cause of 
infusion system contamination is the medical staff’s failure to comply with basic rules of 
infection prevention, which include washing hands and using sterile gloves and masks. One of 
the leading causes of contamination is multiple normal saline withdrawal from one 400 ml 
bottle (5 – 10 ml of normal saline are mixed with a 25000 IU heparin solution to prepare the 
infusion system lock). The 400 ml bottle is not changed within a shift and is stored under 
inadequate conditions. As a result, the absence of pharmaceutical forms for central and 
peripheral venous catheter flushing leads to severe complications and high costs of long-term 
treatment of serious catheter-associated infections. In this regard, TauroPharm’s novel drug – 
TauroLock – is of great interest to physicians. The drug is specifically designed for flushing 
and locking of catheters, ports, and other long-term vascular access systems in cancer patients, 
patients undergoing surgery, patients with cancer, kidney failure, etc. TauroLock contains 
sodium citrate and taurolidine. The former is an anticoagulant and the latter is a new 
antimicrobial agent with a high antibacterial, antiviral and antifungal activity. The drug is so 
efficient in the catheter infection prophylaxis and treatment in cancer patients, that infusion 
system removal is not required. 
According to several studies, the leading cause of catheter-associated infection in patients 
with a totally implantable venous access system is S. epidermidis, which is known to 
colonize mucous membranes and skin and contaminate the port chamber during the needle 
entry despite adherence to the rules of infection prevention. The authors use EMLA cream 
containing lidocaine and prilocaine to provide the topical anesthesia prior to a Huber needle 
insertion into the port chamber. The cream also has antibacterial properties provided that 
the exposition is 40 – 60 minutes. 
3. Results 
The postoperative period was uneventful with only one case of the skin pocket infection 
successfully treated with antibiotics. All the patients feel comfortable with having 
subcutaneous venous access ports. Children have no fear of catheterization prior to yet 
another chemotherapy cycle and are not afraid of Huber needle insertion owing to the use of 
the anesthetizing cream. Since the implantation, all the systems have been functioning 
adequately. Six patients developed the port system thrombosis, which was efficiently coped 
with by means of urokinase introduction into the infusion system with a 15-minute 
exposition. No cases of a catheter-associated infection were reported.  
We use two types of solutions for port system locking between infusions – a 100 IU/ml 
heparin solution and Taurolock (TauroPharm, Germany), a drug specifically designed to be 
used as an infusion system lock. 
4. Conclusion 
The implantable venous port system use in cancer treatment allows physicians to reduce the 
number of invasive procedures, less often resort to general anesthesia, and significantly 
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treatment of serious catheter-associated infections. In this regard, TauroPharm’s novel drug – 
TauroLock – is of great interest to physicians. The drug is specifically designed for flushing 
and locking of catheters, ports, and other long-term vascular access systems in cancer patients, 
patients undergoing surgery, patients with cancer, kidney failure, etc. TauroLock contains 
sodium citrate and taurolidine. The former is an anticoagulant and the latter is a new 
antimicrobial agent with a high antibacterial, antiviral and antifungal activity. The drug is so 
efficient in the catheter infection prophylaxis and treatment in cancer patients, that infusion 
system removal is not required. 
According to several studies, the leading cause of catheter-associated infection in patients 
with a totally implantable venous access system is S. epidermidis, which is known to 
colonize mucous membranes and skin and contaminate the port chamber during the needle 
entry despite adherence to the rules of infection prevention. The authors use EMLA cream 
containing lidocaine and prilocaine to provide the topical anesthesia prior to a Huber needle 
insertion into the port chamber. The cream also has antibacterial properties provided that 
the exposition is 40 – 60 minutes. 
3. Results 
The postoperative period was uneventful with only one case of the skin pocket infection 
successfully treated with antibiotics. All the patients feel comfortable with having 
subcutaneous venous access ports. Children have no fear of catheterization prior to yet 
another chemotherapy cycle and are not afraid of Huber needle insertion owing to the use of 
the anesthetizing cream. Since the implantation, all the systems have been functioning 
adequately. Six patients developed the port system thrombosis, which was efficiently coped 
with by means of urokinase introduction into the infusion system with a 15-minute 
exposition. No cases of a catheter-associated infection were reported.  
We use two types of solutions for port system locking between infusions – a 100 IU/ml 
heparin solution and Taurolock (TauroPharm, Germany), a drug specifically designed to be 
used as an infusion system lock. 
4. Conclusion 
The implantable venous port system use in cancer treatment allows physicians to reduce the 
number of invasive procedures, less often resort to general anesthesia, and significantly 





i.e. to take up sports (including aquatics) and follow regular hygiene procedures. Apart 
from that, the port is almost unnoticeable under the skin. In the case of external venous 
access systems, a chemotherapy cycle could be delayed if it was impossible to gain venous 
access for some reason (inadequate blood count or organ failure that did not allow for 
general anesthesia). With the introduction of implantable port systems each chemotherapy 
cycle can be started on time provided that there are no other counterindications. 
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1. Introduction  
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industrially developed countries, the incidence rate of BC is increasing in Slovenia and has 
reached 111.8 cases per 100,000 women in 2008. The incidence rate of BC has thus shown 
more than a fivefold increase in the period from 1950 to 2008 and BC was diagnosed in 1,147 
women in 2008 (Cancer Registry of Republic of Slovenia, 2010). Similar increases in the 
incidence rates of BC have in the last decades also been observed in a number of other 
economically and industrially developed countries with aging female population (Curado et 
al (Eds.), 2009). However, the incidence rates of the BC are also rapidly increasing in a 
number of low- and middle-income countries (LMIC) (Forouzanfar et al, 2011), with more 
than half of all deaths caused by BC globally occurring in these countries (Curado et al 
(Eds.), 2009; Forouzanfar et al, 2011; International Agency for Research in Cancer, 2008). In 
LMIC countries, a sizeable proportion of women killed by BC were aged 15-49 years 
(Forouzanfar et al, 2011). 
In the period from the year 1954 to the year 2006 a number of demographic changes took place 
in Slovenia (population two million) that may have contributed to the increase in the incidence 
rate of BC in recent decades. Major changes were observed in the size and age of population, 
in the number of live births annually, in the number of live births per 1,000 population, in total 
fertility rate, the age of mother at first birth and the age of mother at birth in total. In detail, the 
population of Slovenia grew from 1,521,485 to 2,008,516 in the period from 1954 to 2006, but 
simultaneously a decrease was observed in the number of live births annually, in the number 
of live births per 1,000 population and in total fertility rate (Ilić et al., 2008). On the other hand, 
an increase was observed in the age of mother at first birth and the age of mother at birth in 
total in the same period (Ilić et al., 2008). The data about population by sex are available only 
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year, 826,145 were men and 887,877 were women. In mid-2006, 986,876 were men and 
1,022,644 were women, and the population of both sexes had been growing older in the 
decades prior to 2006. A substantial increase in the mean age of women at death was observed 
in the period from 1961 to 2006, reflecting an overall increase in age in Slovenian population in 
recent decades (Ilić et al., 2008).  
In this report, the authors assess the possible impact of changes in some of the demographic 
indicators in Slovenia on the increase in the incidence rate of BC and therefore also on the 
possible role of midwives in the early detection and prevention of BC in the future. With 
regard to the recent increases of the incidence rates of BC in a number of LMIC countries, it 
may be plausible to consider the evolution and broadening of the role of midwives in the 
early detection and prevention of BC in these countries as well. 
2. Changes in some of the demographic indicators and simultaneous 
increase in the incidence rate of breast cancer in recent decades in Slovenia 
The data concerning the changes in some of the demographic indicators and simultaneous 
increase in the incidence rate of BC in Slovenia were collected and downloaded from open 
access electronic databases of the National Institute of Public Health of the Republic of 
Slovenia (National Institute of Public Health of the Republic of Slovenia, 2011), Statistical 
Office of the Republic of Slovenia (Statistical Office of the Republic of Slovenia, 2011),  
Slora-Slovenia and Cancer (Slora, 2011) of the Cancer Registry of Republic of Slovenia and 
from some of the similar sources (Cancer Registry of Republic of Slovenia, 2010; Curado et 
al (Eds.), 2009; Ilić et al., 2008). In this report the data in the figures refer only to the period 
from 1961 to 2006 since the data from periods earlier than 1961 are subject to limited 
availability. The data were processed and presented with the use of Excel 97 for Windows 
software package. 
As already mentioned above, BC is the most common type of cancer and most common 
cause of death from cancer in Slovenia (Cancer Registry of Republic of Slovenia, 2010; 
Slora 2011). The incidence rate of BC has been increasing constantly in the last five 
decades (Figure 1). In a large part of this period, from 1961 to 2006, a simultaneous 
decrease had been observed in the number of live births annually, in the number of live 
births per 1,000 population and in total fertility rate (Ilić et al, 2008; Slora, 2011; Statistical 
Office of the Republic of Slovenia, 2011). The number of live births decreased from 31,828 
to 18,932 in the period from 1961 to 2006 (Figure 2), the number of live births per 1,000 
population decreased from 18.1 to 9.4 (Figure 3), and total fertility rate decreased from 
2.26 to 1.31 in the same period (Figure 4). Conversely, for at least a part of this period, 
from late-seventies and early-eighties onward, the age of mother at first birth and the age 
of mother at birth in total both increased (Figure 5) (Ilić et al., 2008; Slora, 2011; Statistical 
Office of the Republic of Slovenia, 2011). The age of mother at first birth increased from 
24.7 years in 1961 to 28 years in 2006, the lowest age of mother at first birth in this period 
was 22.7 years, observed in 1976, and the age of mother at birth in total increased from 
27.7 years in 1961 to 29.7 years in 2006, the lowest age of mother at birth in total in this 
period was 25.3 years, observed in 1979, 1980 and in 1984 (Figure 5). (Ilić et al., 2008; 
Statistical Office of the Republic of Slovenia, 2011). Finally, the mean age at death of 
women increased from 59.8 years in 1954 to 78.1 years in 2006 (Figure 6) (Ilić et al., 2008; 
Slora, 2011; Statistical Office of the Republic of Slovenia, 2011). 
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Fig. 1. Breast cancer crude incidence rate (blue line; definition: crude incidence rate is the 
number of new cases of disease or the number of deceased from the disease, calculated per 
100,000 of population-persons, living in observed population in the middle of the time 
interval, usually one year (Slora, 2011; Statistical Office of the Republic of Slovenia, 2011)) in 
the period from 1961 to 2006 in Slovenia 
Considering the changes in some of the aforementioned demographic factors and the 
corresponding increase in the incidence rate of BC in Slovenia, it is easy to imagine that 
these changes represent an increase in the risk of BC in women in the period from 1961 to 
2006 in this country. Some additional data about changes in population in Slovenia in the 
recent decades in the following text may corroborate this notion. 
As already suggested, the population of both sexes had aged quite rapidly in Slovenia. In 
2006 the mean age of the population overall was 40.7 years; 39 years of men and 42.3 years 
of women. In the period between 1986 and 2006, the population of Slovenia has on average 
grown older by 5.6 years, by the end of this period men were on average older by 5.7 years 
and women by 5.6 years. The mean age of men grew the most between 1997 and 1998, and 
of women between 2001 and 2002 (Ilić et al., 2008). In 2006 the proportion of young 
population aged 0-14 years was 14% and the proportion of population aged 65 years or 
more was 15.7%. In the twenty years from 1986 to 2006 the number of individuals in 
population aged 0-14 years decreased by more than a third (34.8%) and the number of 
individuals in population aged 65 years or more increased by more than a half (59%) (Ilić et 
al, 2008). In just ten years, in the period from 1996 to 2006, the number of women in 
reproductive age (15-49 years) in Slovenia decreased from 518,335 in 1996 to 476,853 in 2006 
(Ilić et al, 2008). In 1954 slightly over a third of children were first-born and almost 20% of 
mothers had at least four children, while in the last three decades of the period from 1954 to 





year, 826,145 were men and 887,877 were women. In mid-2006, 986,876 were men and 
1,022,644 were women, and the population of both sexes had been growing older in the 
decades prior to 2006. A substantial increase in the mean age of women at death was observed 
in the period from 1961 to 2006, reflecting an overall increase in age in Slovenian population in 
recent decades (Ilić et al., 2008).  
In this report, the authors assess the possible impact of changes in some of the demographic 
indicators in Slovenia on the increase in the incidence rate of BC and therefore also on the 
possible role of midwives in the early detection and prevention of BC in the future. With 
regard to the recent increases of the incidence rates of BC in a number of LMIC countries, it 
may be plausible to consider the evolution and broadening of the role of midwives in the 
early detection and prevention of BC in these countries as well. 
2. Changes in some of the demographic indicators and simultaneous 
increase in the incidence rate of breast cancer in recent decades in Slovenia 
The data concerning the changes in some of the demographic indicators and simultaneous 
increase in the incidence rate of BC in Slovenia were collected and downloaded from open 
access electronic databases of the National Institute of Public Health of the Republic of 
Slovenia (National Institute of Public Health of the Republic of Slovenia, 2011), Statistical 
Office of the Republic of Slovenia (Statistical Office of the Republic of Slovenia, 2011),  
Slora-Slovenia and Cancer (Slora, 2011) of the Cancer Registry of Republic of Slovenia and 
from some of the similar sources (Cancer Registry of Republic of Slovenia, 2010; Curado et 
al (Eds.), 2009; Ilić et al., 2008). In this report the data in the figures refer only to the period 
from 1961 to 2006 since the data from periods earlier than 1961 are subject to limited 
availability. The data were processed and presented with the use of Excel 97 for Windows 
software package. 
As already mentioned above, BC is the most common type of cancer and most common 
cause of death from cancer in Slovenia (Cancer Registry of Republic of Slovenia, 2010; 
Slora 2011). The incidence rate of BC has been increasing constantly in the last five 
decades (Figure 1). In a large part of this period, from 1961 to 2006, a simultaneous 
decrease had been observed in the number of live births annually, in the number of live 
births per 1,000 population and in total fertility rate (Ilić et al, 2008; Slora, 2011; Statistical 
Office of the Republic of Slovenia, 2011). The number of live births decreased from 31,828 
to 18,932 in the period from 1961 to 2006 (Figure 2), the number of live births per 1,000 
population decreased from 18.1 to 9.4 (Figure 3), and total fertility rate decreased from 
2.26 to 1.31 in the same period (Figure 4). Conversely, for at least a part of this period, 
from late-seventies and early-eighties onward, the age of mother at first birth and the age 
of mother at birth in total both increased (Figure 5) (Ilić et al., 2008; Slora, 2011; Statistical 
Office of the Republic of Slovenia, 2011). The age of mother at first birth increased from 
24.7 years in 1961 to 28 years in 2006, the lowest age of mother at first birth in this period 
was 22.7 years, observed in 1976, and the age of mother at birth in total increased from 
27.7 years in 1961 to 29.7 years in 2006, the lowest age of mother at birth in total in this 
period was 25.3 years, observed in 1979, 1980 and in 1984 (Figure 5). (Ilić et al., 2008; 
Statistical Office of the Republic of Slovenia, 2011). Finally, the mean age at death of 
women increased from 59.8 years in 1954 to 78.1 years in 2006 (Figure 6) (Ilić et al., 2008; 
Slora, 2011; Statistical Office of the Republic of Slovenia, 2011). 
Early Detection and Prevention of Breast Cancer:  




Fig. 1. Breast cancer crude incidence rate (blue line; definition: crude incidence rate is the 
number of new cases of disease or the number of deceased from the disease, calculated per 
100,000 of population-persons, living in observed population in the middle of the time 
interval, usually one year (Slora, 2011; Statistical Office of the Republic of Slovenia, 2011)) in 
the period from 1961 to 2006 in Slovenia 
Considering the changes in some of the aforementioned demographic factors and the 
corresponding increase in the incidence rate of BC in Slovenia, it is easy to imagine that 
these changes represent an increase in the risk of BC in women in the period from 1961 to 
2006 in this country. Some additional data about changes in population in Slovenia in the 
recent decades in the following text may corroborate this notion. 
As already suggested, the population of both sexes had aged quite rapidly in Slovenia. In 
2006 the mean age of the population overall was 40.7 years; 39 years of men and 42.3 years 
of women. In the period between 1986 and 2006, the population of Slovenia has on average 
grown older by 5.6 years, by the end of this period men were on average older by 5.7 years 
and women by 5.6 years. The mean age of men grew the most between 1997 and 1998, and 
of women between 2001 and 2002 (Ilić et al., 2008). In 2006 the proportion of young 
population aged 0-14 years was 14% and the proportion of population aged 65 years or 
more was 15.7%. In the twenty years from 1986 to 2006 the number of individuals in 
population aged 0-14 years decreased by more than a third (34.8%) and the number of 
individuals in population aged 65 years or more increased by more than a half (59%) (Ilić et 
al, 2008). In just ten years, in the period from 1996 to 2006, the number of women in 
reproductive age (15-49 years) in Slovenia decreased from 518,335 in 1996 to 476,853 in 2006 
(Ilić et al, 2008). In 1954 slightly over a third of children were first-born and almost 20% of 
mothers had at least four children, while in the last three decades of the period from 1954 to 





third of births were second order births (35.8% in 2006), slightly more than 10% were third 
order births (10.9% in 2006) and only about 3% of births were fourth order births or higher 
(3.7% in 2006) (Ilić et al., 2008).  
 
Fig. 2. Number of live births (red line; definition: number of live born children in the 
calendar year) in the period from 1961 to 2006 in Slovenia  
In addition, it was also possible to retrieve some further data, for the period from 1954 to 
1961, for the age of mother at first birth and the age of mother at birth in total, both risk 
factors for BC. Altogether, the age of mother at first birth rose from 24.8 years in the year 
1954 to 28.0 years in the year 2006. The age of mother at birth in total rose from 28.4 years in 
1954 to 29.7 years in 2006 (Ilić et al, 2008). Postponement of birth of the first child is typical 
for women of many European Union countries, especially in the lowest-low fertility 
countries. In some of these countries the trends in postponing of births is so intense that 
annual increase in the mean age is 0.2 years, with extremely fast postponement occurring in 
Slovenia, Hungary and the Czech Republic. In the United Kingdom, the mean age of women 
that gave birth to their children for the first time reached 30 years in 2006 (Ilić et al, 2008). 
On the whole, increased risk of BC is associated with female gender, advancing age and age 
during menstrual life, hormonal factors (early menarche and late menopause), nulliparity 
and age of over 30 years at first birth, obesity and estrogen therapy after the menopause, 
harmful drinking of alcohol and history of benign proliferative lesions in the breast 
(Armstrong & Nguyen, 1999; Bryant, 2004; Cancer Registry of Republic of Slovenia, 2010; 
Curado et al (Eds.), 2009; Henderson et al, 1996; International Agency for Research in 
Cancer, 2008; Soerjomataram et al, 2008). Risk of BC is also increased in women with one or 
more first-degree relatives with BC (Henderson et al, 1996), and with inherited mutations of 
any one of major genes, like BRCA1, BRCA2 and several others (Armstrong & Nguyen, 
1999; International Agency for Research in Cancer, 2008).  
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Fig. 3. Number of live births per 1,000 population (red line; definition: ratio between the 
number of live born children in the calendar year and the same mid-year population, 
multiplied by 1,000 (Ilić et al., 2008)) in the period from 1961 to 2006  in Slovenia 
 
Fig. 4. Total fertility rate (red line; definition: the average number of live born children per 
one woman in reproductive age (15-49 years) in the calendar year (Ilić et al., 2008)) in the 
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It may be of particular interest that the number of women diagnosed with BC in the year 
2008 in Slovenia is slightly lower than in the year 2007, when the incidence rate of BC 
reached 112.9 cases per 100,000 and when BC was diagnosed in 1,156 women (Cancer 
Registry of Republic of Slovenia, 2010; Slora, 2011). However, the incidence rates of BC are 
still notably lower in Slovenia than in the United States of America and in a number of other 
developed European Union countries. It remains to be seen if this small decrease in the 
incidence rate of BC in Slovenia represents the same type of trend as observed in the United 
States of America, where the incidence rates of BC decreased by approximately two percent 
annually in the period from 1999 to 2005 (Centers for Disease Control and Prevention, 2007; 
Kerlikowske et al, 2007). Later analysis showed that the incidence rate for BC stabilized in 
the period from 2003 to 2007, following a sharp decrease between 2002 and 2003 observed in 
women aged 50 years or more (DeSantis et al, 2011a, 2011b), that was associated with the 
decrease in the use of postmenopausal hormonal replacement therapy (DeSantis et al, 2011b; 
Kohler et al. 2011; Ravdin et al, 2007). 
 
Fig. 5. Mean age mother at first birth (dark red line) and mean age of mother at birth-total 
(light red line) in the period from 1961 to 2006 in Slovenia 
All these data to point to changes in the quantity and quality of the work performed at 
present by midwives employed in the thirteen maternity wards and maternity hospitals, 
and elsewhere in Slovenia (National Institute of Public Health of the Republic of Slovenia, 
2011). The possible role of midwives in the early detection and prevention of BC in the 
future should thus be carefully appraised and evaluated. 
3. Midwives and breast cancer screening 
Study of midwifery has a long and distinguished tradition in Slovenia. The first School for 
midwives was established in 1753 in Ljubljana, the capital of Slovenia, following the decree 
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issued by Maria Theresa, Empress of Austria, sovereign of all Slovenian lands at that time. 
Similar Schools for midwives were later also established in Graz, Celovec (Klagenfurt) and 
Trst (Trieste), all of them at least partly serving the Slovenian-speaking population. After 
1924 Midwifery school in Ljubljana remained the only institution which educated midwives 
in Slovenia. At present the first-cycle degree Professional Higher Education Study 
Programme Midwifery at the Faculty of Health Sciences at the University of Ljubljana lasts 
three years (six semesters) and 30 students enrol in the programme each year. The majority 
of the enrolled students finish the study program and complete their study with a diploma 
work (Skoberne et al, 2011; Stanek Zidarič et al., 2009).  
 
Fig. 6. Mean age of death in women (red line) in the period from 1961 to 2006 in Slovenia 
Although it is not particularly emphasized in their curriculum (Stanek Zidarič et al., 2009; 
World Health Organization & WHO Regional Office for Europe, 2001), midwifery students 
at the Faculty of Health Sciences in Ljubljana get a reasonable amount of insight into 
anatomy, histology and physiology of breasts, as well as into incidence, clinical and 
pathological characteristics, treatment and mortality of BC. They also learn some of the 
fundamentals about how to perform breast self-examination (BSE) and clinical breast 
examination (CBE) (Plesničar et al., 2004a; Plesničar et al., 2010; Stanek Zidarič et al., 2009). 
As a result, midwifery students have a favourable attitude toward BSE, they are of opinion 
that teaching BSE helps in detection of BC, and that teaching other women how to practice 
BSE ought to be one of their duties. They are also optimistic in their views of development 
and efficacy of BC detection and treatment in the future. This sort of attitude toward BC and 
BSE may have emerged from their specific education and from their inherent motivation to 
learn as much as possible about clinical, psychological and other problems that affect 
women with this disease (Plesničar et al., 2004a; Plesničar et al., 2010). All these qualities 
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Frank et al, 2000; Gigerenzer et al, 2009; Jirojwong & MacLennan, 2002; Plesničar et al., 
2004a; Plesničar et al., 2010). It should also be taken into account that due to their specific 
education and positive attitude toward BSE, midwifery students should be at the end of 
their study able to teach BSE to other women and perform CBE quite efficiently (Boulos et 
al, 2005; Miller et al., 2000; Mittra et al, 2010; Plesničar et al., 2004a; Plesničar et al., 2010). 
In the majority of developed countries, including Slovenia, the emphasis is on the use of 
mammography screening tests focused on early BC detection. These tests enable the 
discovery of the disease in the early stages of its clinical development, thus improving the 
chances of longer survival of BC patients (Armstrong & Nguyen, 1999; Dora-državni 
presejalni program za raka dojk, 2011; Frank et al, 2009; U.S. Preventive Services Task Force. 
2009). In a number of studies, however, mammography screening has been shown to reduce 
breast cancer mortality significantly only for women aged 50–74 years. No benefit has been 
shown for CBE or BSE (Gøtzsche & Nielsen, 2011; Jekel et al, 1996; Nelson et al, 2009). In 
addition, some of the studies have, among other problems, also pointed to disagreements 
about mammography screening tests' efficacy (Gøtzsche & Nielsen, 2011). Harms of BC 
mammography screening were found to include false-positive results, biopsies and repeated 
imaging in women without cancer, risks of unnecessary treatment, increased radiation 
exposure and psychological damage (Gøtzsche & Nielsen, 2011; Meissner et al, 2011; U.S. 
Preventive Services Task Force, 2009; Welch & Black, 2010). Contrariwise, in Canadian 
National Breast Screening Study-2 trial mammography with CBE was compared to CBE 
alone in women aged 50-59 years and no difference in mortality from BC was observed 
between the two approaches at 13 years (Miller et al, 2000). These controversies have led to 
suggestions that decisions about participation in mammography screening tests for women 
should be made on an individualized basis (Berlin & Hall, 2010; Hall, 2009; Meissner et al, 
2011; Peres, 2010; Plesničar et al, 2010). The approach that requires work with women on an 
individual basis should certainly include greater sharing of information and decision 
making between patient or client and health expert, be that midwife, physician or nurse 
(Berlin & Hall, 2010; Hall, 2009; Peres, 2010). 
In Slovenia primary health care includes specialists in family medicine, paediatrics, 
psychiatry and gynaecology (Ministry of Health & Government of Republic of Slovenia, 
2011b; National Institute of Public Health of the Republic of Slovenia, 2011; Statistical Office 
of the Republic of Slovenia, 2011). In the year 2011 a number of family practices were 
upgraded to referral practices, in effect multidisciplinary teams, each one comprising a 
specialist in family medicine, a nurse and a certified nurse that perform certain activities in 
accordance with her/his jurisdiction and responsibilities. The aim of such referral practices 
is to increase quality, safety and cost effectiveness in patient treatment by transferring a 
number of tasks to the primary level. It is anticipated that each referral practice is involved 
in optimal integrated care adhering to chronic patient treatment protocols, prevention and 
optimal use of laboratory services of at least four of the following chronic conditions and 
treatments: heart failure, chronic obstructive pulmonary disease, asthma, depression, 
diabetes, benign hypertrophy of the prostate, thyroid diseases and anti-coagulation 
treatment (Ministry of Health & Government of Republic of Slovenia, 2011b).  
Following the aforementioned model of referral practices, it could probably be relatively easy 
to establish multidisciplinary teams that would among other activities also focus on early 
detection and prevention of BC. Each such team could comprise a specialist in gynaecology 
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and obstetrics, a midwife and/or a nurse. In some circumstances, for example those distinctive 
of LMIC countries, midwives could perform their specific activities associated with BC alone. 
At least in the beginning, midwives could perform CBE as recommended in prevailing 
guidelines (Boulos et al, 2005; Meissner et al, 2011; Mittra et al, 2010; Plesničar et al, 2010; U.S. 
Preventive Services Task Force, 2009). Besides performing CBE with or without 
mammography, the activity of midwives could expand to informing women about breast 
health awareness (BHA). For women, accepting BHA would mean getting unbiased 
information about a wide range of breast problems such as breast pain and tenderness, breast 
asymmetry, nipple discharge, breasts considered to be too small or too large, or about breast 
lumps, bumps and thickenings (Mitchell, 2002). It would also mean being able to recognize 
normal appearance and structure of breasts during different periods of menstrual cycle and 
with regard to pregnancy and age, to recognize undue changes and inform midwife and 
physician in the multidisciplinary team about them immediately so they could refer these 
women to mammography tests when necessary (Mitchell, 2002; Plesničar et al., 2004b). 
Although BSE does not decrease BC mortality (Semiglazov et al, 2004; Thomas et al, 2002; U.S. 
Preventive Services Task Force, 2009), it can be regarded as an essential component of BHA 
that may contribute to early BC detection (Mitchell, 2002; Plesničar et al., 2010). Breast self-
examination is not much different from what the concept of BHA includes (Dowle et al, 1987; 
Philip et al, 1984; Plesničar et al., 2010) and in some opinions BHA should broaden the role of 
BSE (Austoker, 2003; Plesničar et al., 2010). The easiest way to increase BHA could thus be to 
teach BSE, and in this manner the role of midwives in early BC detection would be given even 
more prominence (Miller et al., 2000; Plesničar et al., 2004a, Plesničar et al., 2010). 
Further on, midwives could take part in BC risk factor reduction or elimination and some 
other specific health promotion activities, all of them part of primary prevention, that would 
focus on introducing subtle and hardly measurable changes in women's and population's way 
of living with the aim of decreasing BC incidence in the longer term in Slovenia and elsewhere. 
These activities could include education about health behaviour modification with prolonged 
lactation, healthy lifestyle with regular physical activity, and proper nutrition to prevent 
obesity and harmful consumption of alcohol. For postmenopausal women these activities 
could also include the information about the risks of the use of hormonal replacement therapy 
(Armstrong & Nguyen, 1999; Anderson et al 2008, DeSantis et al, 2011b; Henderson et al, 1996; 
Jekel et al, 1996; Kohler et al. 2011; Ravdin et al, 2007). All these activities and procedures 
would be carried out on an individual basis, in time gradually replacing mammography 
screening with individual BC case finding (Jekel et al, 1996).   
Finally, it may be appropriate to cite comments of Otis Brawley, MD, chief medical officer of 
the American Cancer Society, with regard to prostate cancer screening and simply substitute 
the word breast for prostate (Berlin & Hall, 2010) and make a mention of midwives in the 
context: adequately trained and experienced midwives could help every woman take an 
informed decision about what is right for her personally after hearing a balanced presentation 
of potential benefits and risks of screening. All in the medical and advocacy communities 
should respect that choice (Brawley, 2009, as cited in Berlin & Hall, 2010) 
4. Discussion 
The changes in demographics and in the incidence rate of BC in the last decades surely 
represent serious and important challenges for health care system in Slovenia. Despite the 
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contents of midwifery students’ curriculum, the numbers of maternity wards and maternity 
hospitals have remained more or less constant and without sensible changes in recent years.  
All the data about changes in demographic indicators with potential impact on the increase 
of BC incidence rates in Slovenia may not have been shown in this report. However, the 
changes in number of live births, number of live births per 1,000 population, total fertility 
rate, age of mother at first birth and age of mother at birth in total, and mean age of death in 
women in the period from 1961 to 2006, certainly suggest that there are now many more 
women exposed to the risk of BC than four or five decades ago (Armstrong & Nguyen, 1999; 
Bryant, 2004; Curado et al (Eds.), 2009; Henderson et al, 1996; International Agency for 
Research in Cancer, 2008; Soerjomataram et al 2008). The changes in demographic indicators 
and the increase in the incidence rate of BC in Slovenia in the last decades should at the very 
least stimulate a debate about changes in priorities in activities of midwives and related 
experts and specialists today and in the future. One of the future priorities for midwives 
could be early detection and prevention of BC that would include informing women about 
BHA and about risk factors of BC on an individual basis. In Slovenia and some other 
countries midwives already occupy a central position in education of young women about 
sexual and reproductive health, family planning and contraception (Ministry of Health & 
Government of Republic of Slovenia, 2011a). It should not be difficult to imagine the 
midwives establishing a trustful and confidential professional relationship with women in 
late teens or early twenties, informing them about BHA, BSE, CBE, BC, age adjusted BC risk 
factors and their reduction or elimination, performing CBE according to guidelines and later 
in their lives informing them about BC mammography screening programs. 
About two thirds of all cancer cases are diagnosed in economically developed countries and 
about one third in LMIC countries (Forouzanfar et al, 2011; International Agency for 
Research in Cancer, 2008; Mellstedt, 2006). In the year 2010 the majority of women with BC 
in economically and industrially developed countries were aged 50 years or more. However, 
in developing countries there were twice as many women with BC aged 15-49 years than in 
developed countries, with the incidence rate of BC overall rising rapidly (Forouzanfar et al, 
2011; International Agency for Research in Cancer, 2008; Mittra, 2011; Yeole & Kurkure, 
2003). In view of these developments, it is agreed that mammography is not an appropriate 
BC screening test for LMIC countries. It is expensive, technologically complex and requires 
highly skilled experts and quality control (Berlin & Hall, 2010; Frank et al, 2000; Harford, 
2011; Mittra, 2011; Nelson et al, 2009; U.S. Preventive Services Task Force, 2009). Conversely, 
CBE is relatively easy and inexpensive to perform (Mittra, 2011; Nelson et al, 2009). 
However, its effectiveness in reducing BC mortality is still regarded as controversial (Nelson 
et al, 2009), although the results of Canadian National Breast Screening Study-2 strongly 
suggest such an effect (Miller et al, 2000; Mittra, 2011). Two major randomized trials in 
Mumbai and Cairo comparing CBE and no screening are now addressing this dilemma. In 
Mumbai CBE and education are performed by female health workers who underwent five 
months of additional training, while in Cairo examinations are performed by female 
physicians who received two months of special training (Boulos et al, 2005; Mittra et al, 
2010). In both studies there have been difficulties in assuring follow-up, a problem in many 
cases due to low levels of health awareness and motivation in screened communities (Miller, 
2008; Mittra et al, 2010; Mittra, 2011). It is intriguing to speculate that this problem may 
otherwise not be encountered in Slovenia or other developed countries. These two studies 
may confirm the effectiveness of CBE and its use in LMIC countries may obviate the 
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perceived need for establishing complex mammography screening programs, especially 
since a large proportion of women diagnosed with BC in these countries are aged 15-49 
years.  
The results of Mumbai and Cairo studies may strengthen the arguments for use of CBE by 
midwives in Slovenia and elsewhere. Altogether, the activities of midwives working with 
women on an individual basis, whether alone or as a part of a multidisciplinary team in a 
referral practice, including informing and teaching women about BHA, giving other 
information and performing CBE, could be described as lifetime breast health monitoring, a 
development of practice described already more than thirty years ago (Breslow & Somers, 
1977). 
5. Conclusion  
It is imperative to understand the need to change and supplement secondary prevention of 
BC from mammography screening to individual BC case finding that would include 
mammography when necessary. In the future, individual BC case finding should be further 
developed to lifetime breast health monitoring, making midwives role in multidisciplinary 
teams indispensable. In certain surroundings and circumstances, especially in LMIC 
countries, midwives could also operate alone. In Slovenia and other parts of the world, 
including LMIC countries, where increasing incidence rate of BC and demographic changes 
represent a serious public health issue, their skills, proficiency, positive attitudes and 
goodwill should not be left unused.   
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contents of midwifery students’ curriculum, the numbers of maternity wards and maternity 
hospitals have remained more or less constant and without sensible changes in recent years.  
All the data about changes in demographic indicators with potential impact on the increase 
of BC incidence rates in Slovenia may not have been shown in this report. However, the 
changes in number of live births, number of live births per 1,000 population, total fertility 
rate, age of mother at first birth and age of mother at birth in total, and mean age of death in 
women in the period from 1961 to 2006, certainly suggest that there are now many more 
women exposed to the risk of BC than four or five decades ago (Armstrong & Nguyen, 1999; 
Bryant, 2004; Curado et al (Eds.), 2009; Henderson et al, 1996; International Agency for 
Research in Cancer, 2008; Soerjomataram et al 2008). The changes in demographic indicators 
and the increase in the incidence rate of BC in Slovenia in the last decades should at the very 
least stimulate a debate about changes in priorities in activities of midwives and related 
experts and specialists today and in the future. One of the future priorities for midwives 
could be early detection and prevention of BC that would include informing women about 
BHA and about risk factors of BC on an individual basis. In Slovenia and some other 
countries midwives already occupy a central position in education of young women about 
sexual and reproductive health, family planning and contraception (Ministry of Health & 
Government of Republic of Slovenia, 2011a). It should not be difficult to imagine the 
midwives establishing a trustful and confidential professional relationship with women in 
late teens or early twenties, informing them about BHA, BSE, CBE, BC, age adjusted BC risk 
factors and their reduction or elimination, performing CBE according to guidelines and later 
in their lives informing them about BC mammography screening programs. 
About two thirds of all cancer cases are diagnosed in economically developed countries and 
about one third in LMIC countries (Forouzanfar et al, 2011; International Agency for 
Research in Cancer, 2008; Mellstedt, 2006). In the year 2010 the majority of women with BC 
in economically and industrially developed countries were aged 50 years or more. However, 
in developing countries there were twice as many women with BC aged 15-49 years than in 
developed countries, with the incidence rate of BC overall rising rapidly (Forouzanfar et al, 
2011; International Agency for Research in Cancer, 2008; Mittra, 2011; Yeole & Kurkure, 
2003). In view of these developments, it is agreed that mammography is not an appropriate 
BC screening test for LMIC countries. It is expensive, technologically complex and requires 
highly skilled experts and quality control (Berlin & Hall, 2010; Frank et al, 2000; Harford, 
2011; Mittra, 2011; Nelson et al, 2009; U.S. Preventive Services Task Force, 2009). Conversely, 
CBE is relatively easy and inexpensive to perform (Mittra, 2011; Nelson et al, 2009). 
However, its effectiveness in reducing BC mortality is still regarded as controversial (Nelson 
et al, 2009), although the results of Canadian National Breast Screening Study-2 strongly 
suggest such an effect (Miller et al, 2000; Mittra, 2011). Two major randomized trials in 
Mumbai and Cairo comparing CBE and no screening are now addressing this dilemma. In 
Mumbai CBE and education are performed by female health workers who underwent five 
months of additional training, while in Cairo examinations are performed by female 
physicians who received two months of special training (Boulos et al, 2005; Mittra et al, 
2010). In both studies there have been difficulties in assuring follow-up, a problem in many 
cases due to low levels of health awareness and motivation in screened communities (Miller, 
2008; Mittra et al, 2010; Mittra, 2011). It is intriguing to speculate that this problem may 
otherwise not be encountered in Slovenia or other developed countries. These two studies 
may confirm the effectiveness of CBE and its use in LMIC countries may obviate the 
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perceived need for establishing complex mammography screening programs, especially 
since a large proportion of women diagnosed with BC in these countries are aged 15-49 
years.  
The results of Mumbai and Cairo studies may strengthen the arguments for use of CBE by 
midwives in Slovenia and elsewhere. Altogether, the activities of midwives working with 
women on an individual basis, whether alone or as a part of a multidisciplinary team in a 
referral practice, including informing and teaching women about BHA, giving other 
information and performing CBE, could be described as lifetime breast health monitoring, a 
development of practice described already more than thirty years ago (Breslow & Somers, 
1977). 
5. Conclusion  
It is imperative to understand the need to change and supplement secondary prevention of 
BC from mammography screening to individual BC case finding that would include 
mammography when necessary. In the future, individual BC case finding should be further 
developed to lifetime breast health monitoring, making midwives role in multidisciplinary 
teams indispensable. In certain surroundings and circumstances, especially in LMIC 
countries, midwives could also operate alone. In Slovenia and other parts of the world, 
including LMIC countries, where increasing incidence rate of BC and demographic changes 
represent a serious public health issue, their skills, proficiency, positive attitudes and 
goodwill should not be left unused.   
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1. Introduction 
One of the most commonly diagnosed cancers is non-small cell lung cancer (NSCLC), which 
is the leading cause of lung cancer related deaths throughout the world 1;2. NSCLC is an 
aggressive tumor having poor surveillance. Patients with NSCLC have only 15% or less five 
year survival rate 3. Many genetic abnormalities involved in the pathogenesis of NSCLC e.g. 
mutation in the p53 gene a tumor suppressor gene. 
Chemokines; a superfamily of cytokines, low molecular weight (8-10kDa) proteins, are 
chemo-attractants for leukocytes and chemokines contains more than 40 ligands and 20 
receptors 4;5. Chemokines can be grouped into four sub families on the basis of the first two 
of four conserved cysteine residues, functional activity and receptor binding properties and 
are abbreviated as C, CC, CXC and CX3C. 
C chemokines or γ chemokines contains only two cysteines residues; one cysteine present at 
amino terminal and second present downstream, present in thymus and are 
chemoattractant for T cell precursors. 
CC chemokines are also called as ß-chemokines, have two adjacent cysteines at their N-
terminal. These proteins induce the migration of immune cells, mainly dendritic cells, 
natural killer cells and monocytes. 
CXC chemokines or α-chemokines are those in which single amino acid separates two 
adjacent cysteines present at N- terminal, thus have an "X" in their name. These are divided 
into two groups, ELR positive and ELR-negative. 
In CX3C chemokines or d-chemokines, two cysteines are separated by three amino acids. It 
acts in an autocrine manner i.e. secreted and act on the same cell.  
Chemokines have an important role in pro-inflammatory as well as non-inflammatory cell 
homing 6. Chemokines cause the migration of leukocytes to inflammatory sites and also play 
role in the hematopoietic stem cells regulation, angiogenesis and the extracellular matrix. 
This super-family also plays additional role in diverse fields including development, 
immunology and cancer. 
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Chemokines also play an important role in the neoplastic transformation of a cell, encourage 
angiogenesis, tumor colonial expansion and changes in EMC and also mediate organ 
specific metastasis during carcinogenesis 7;8. Tumor metastatic potential can be determined 
by the tumor microenvironment and target organs 9;10. 
Chemokine receptors are G protein coupled receptors and numerous cells show the 
expression of these receptors including leukocytes, endothelial cells, stromal cells, epithelial 
cells and tumor cells 10-12. These receptors have vital roles in malignant tumor and 
cardiovascular diseases, also play role in allergic reactions, tissue damage and microbial 
infections 13;14. Chemokine receptors are classified into four subfamilies on the basis of four 
subfamilies of chemokines they bind, CXCR, CCR, CX3CR and XCR.  
Chemokine receptors play major role in tumor metastasis 14-16. At each step of metastasis 
these receptors potentially facilitate tumor dissemination. In order to estimate the clinical 
significance of these receptors few clinical studies have been done. But there is no 
comprehensive study regarding all the chemokine receptors in NSCLC 17-19. 
2. Expression of CXCL8 in NSCLC 
In cancers having angiogenic phenotypes like NSCLC, CXCL8 is a very effective and 
powerful angiogenic factor. Its receptors are CXCR1 and CXCR2 20.Tumor angiogenesis, 
metastasis and poor survival rate is related to high level of CXCL8 21-23. 
CXCL8 directly promotes proliferation of endothelial cell, chemo taxis and tubular 
morphogenesis 24-26. CXCL8 was identified in a gene expression of patients that were 
predictive of poor prognosis with stage 1 lung cancer 7;27. 
Two of the six cell lines of NSCLC expressed high levels of CXCL8, these cell lines are A549 
and H441, while the other cell lines expressed low levels of CXCL8. Earlier studies assumed 
that only cancer cells produce CXCL8. However stromal cells secrete high level of CXCL8 
and also increase tumor cells in tumor and stromal cells co-culture. Mechanism of this 
induction is still undefined. In several in-vitro models, cell to cell contact is involved in the 
induction of CXCL8 20. Role of CXCL8 in lung cancer is not obvious. CXCL8 receptors are 
present on lung cancerous cells but their effect on tumor angiogenesis and proliferation is 
still uncertain. 
CXCR1 is a major receptor of CXCL8 which allows or influence the mitogenic activity of it in 
NSCLC. Thus, targeting mitogenic and angiogenic activity of CXCL8 may help to control 
tissue invasion and metastasis of NSCLC 20. Circulating human CXCL8 can be a valuable, 
clinically applicable tumor protein marker owed to its affirmative correlation by means of 
numerous physiologic variables related by lung cancer progression. 
3. Expression of CXCL5 & CXCL12 in NSCLC 
CXCL5 is an important mediator of angiogenesis in NSCLC. In different experimental 
studies, it is observed that angiogenesis in NSCLC is directly correlated to higher level of 
CXCL5 28. 
Surgical specimens of NSCLC show a direct link between tumor angiogenesis and CXCL5. 
In SCID mice, CXCL5 expression was directly related to tumor proliferation and metastasis.  
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Reduction of CXCL5 expression, reduce tumor proliferation and metastases 28.This was also 
suggested by recent studies that the presence of CXCL5 in NSCLC have higher degree of 
correlation with both tumor proliferation and patient prognosis 21;29. 
CXCL12 with CXCR4 had also been involved in stimulating angiogenesis of NSCLC 30;31. 
However, recent experimental studies of NSCLC make it clear that CXCR4 is expressed on 
cancerous cells and does not stimulate tumor angiogenesis in an in vivo culture. In this 
experimental study, with reduction of CXCL12 level, no significant change in primary 
tumor size and tumor angiogenesis was observed 32. 
However, there is an obvious reduction of metastasis of these tumors into in vitro culture, 
indicating that the CXCL12/CXCR4 promotes metastasis and proliferation of the tumor cells. 
A reason for this noticeable difference of these in vivo studies from other in vitro studies of 
angiogenesis mediated by CXCL12/CXCR4 is that CXCR4 expressing tumor cells can 
“outcompete” tumor-associated endothelial cells for CXCL12. Therefore, there is a very great 
difference in the function of CXCL12 against the other factors associated with angiogenesis, 
such that metastasis is promoted by CXCL5, CXCL8, and vascular endothelial growth factors. 
CXCL5 & CXCL12 receptors over expression in tumor tissues possibly will suggest the 
development of diagnostic agents and therapy targeted at chemokine receptor–over 
expressing tumors. In this regard only some exhaustive clinical studies have been 
undertaken to assess the clinical importance of these receptors status but no comprehensive 
study has been known in NSCLC. 
4. Expression of CXCR1& CXCR2 
There are two cell surface receptors which bind to CXCL8, known as CXCR1 and CXCR2; 
these receptors have similar structure but different binding sites 33. CXCR1 binds only with 
one CXC chemokine, CXCL8, while CXCR2 binds to numerous CXC chemokines. These 
receptors are present on different cell types including leukocytes, keratinocytes, endothelial 
cells 34;35 and various tumor cells including NSCLC36;37.  
When functions of CXCL8 and importance of its receptors, CXCR1 and CXCR2 were 
observed in different cancer cell lines, it was found that an increased level of CXCL8 
mediated cell invasion and migration is directly correlated with increased expression of 
CXCR1 &CXCR2. By using different neutralizing antibodies, it was observed that CXCR1 
was not involved in cell migration and invasion, only CXCR2 was involved, while both 
receptors are involved in angiogenesis. Thus making strategies against CXCL8 signaling 
pathways promises a better therapy of cancer. It is demonstrated by several studies that 
CXCR2 is responsible for CXCL8 mediated angiogenesis in NSCLC and human micro 
vascular endothelial cells 24;38;39. 
CXCR1 is an important receptor which promotes the function of CXCL8. Thus targeting 
expression of CXCR1 & production of CXCL8 may ultimately help to develop strategies 
against lung cancer proliferation, invasion and metastasis.  
5. Expression of CXCR4 
CXCR4 is receptor for chemokine CXCL12. In NSCLC, tumor cells at stage 1 show 
expression of CXCR4, present in the nucleus and cytoplasm of these tumor cells. Several 
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studies on tumor cells show that CXCR4 positive nuclear staining is related with improve 
survival rate. The 5 year overall survival rate was 93% for the patients having strong nuclear 
staining 52% for those having weak nuclear staining 10. 
CXCL12 and its receptor CXCR4 promote metastasis of different tumors having angiogenic 
phenotype including NSCLC 17;32;40-42.CXCR4 may transform a benign tumor to malignant 
phenotype 17;43. 
6. Expression of CXCR7 
It was previously thought that CXCL12 has only one surface receptor, CXCR4, but Burns 
and colleagues 14;44 characterized that another receptor CXCR7 binds CXCL12. CXCR7 
together with CXCR3 also has another ligand CXCL11. CXCR7 presents on many cell lines 
including cancer cell lines, fetal liver cells and activated endothelial cells. It facilitates 
angiogenesis and the blockage of CXCR7 inhibits tumor growth in mouse models. 
Patients with EGFR gene mutations show high level of CXCR7 expression. Choi and 
colleagues reported that mutations in one EGFR domain, tyrosine kinase are responsible for 
phosphorylation of EGFR, tyrosine independent mutations and caused constant activation 
of EGFR 14;45. 
Molecular analysis of tumor of patients that took part in the TRIBUT or IDEAL/INTAC 
experimental study revealed that patients with improve prognosis had an EGRF mutated 
tumor. This is one of the explanations that CXCR7 is an independent disease free prognostic 
factor 14. 
Wang and colleagues by using qualitative mRNA characterized that increasing tumor grade 
show increased expression of CXCR7 in prostate cancer. Fluorescence activated cell sorting 
analysis also indicated higher CXCR7 expression 46. 
In conclusion higher expression of CXCR7 is linked with tumor metastasis and poor 
survival of patients with P-stage1 NSCLC. As the elevated CXCR7 expression is directly 
correlated with increased EGFR gene mutations, therefore the expression of CXCR7 is not 
the only one factor for overall survival. We can also say that in future, studies of CXCR7 
possibly will lead on the road to the development of diagnostic agents and targeted therapy 
for patients with p-stage I NSCLC. 
7. Expression of receptors in tumor islets 
Survival of NSCLC patients is directly related to CXCR2, CXCR3 and CXCR4 expression in 
tumor stroma. Expression of CXCR3 and CCR1 is also positively correlated to increase in 
number of mast cells and islet macrophages. The chemokine receptor CCR1 is present on 
macrophages and involved in the migration of macrophages into tumor islets. CCR1 is a 
receptor of CCL3 protein. TNF-α production and release is stimulated by CCL1 and has 
cytotoxic potential in tumor islets. Natural killer cells, T lymphocytes and mast cells show 
the expression of CXCR3; there is no evidence of expression of CXCR3 on macrophages 4;47-
49. These immune cells are linked with increase survival in NSCLC and together with 
macrophages involved tumor killing 4;19;50;51. 
The tumors enriched for cells expressing CXCR3, having large quantities of one or all of the 
CXCR3 binding chemokines including CXCL9, CXCL10 and CXCL11. Host anti tumor 
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immune response is mediated by expression of CXCR3 on various immune cells in mouse 
model. CXCR3 binding chemokines are secreted by a variety of inflammatory and structural 
cells and act as indicating markers for Th1 immunological 4;52. 
In NSCLC, CCL5 produced by tumor epithelial cells and involved in determination of the 
nature and intensity of the immune response. While CXCR2 is not expressed in epithelial 
cells of the tumor islets, but is expressed on inflammatory cells. Expression of CXCR2 is 
directly correlated with increased survival. So it is suggested that neoplastic transformation 
is promoted by reduction of CXCR2 expression on epithelial cells in NSCLC. It is also 
suggested that expression of CXCR2 on inflammatory cells used to limit tumor proliferation. 
There is dichotomy in function of CXCR2 in NSCLC.  In the stroma, it acts as an angiogenic 
factor and helps in tumor proliferation, but on the other side by the recruitment of the 
inflammatory cells to tumor islet, it limits tumor growth. Thus targeting CXCR2 has 
unpredictable effects depending on the relative balance between these two different 
functions 4. 
Conclusively, this information can be considered to target the chemokines and chemokine 
receptors to establish the therapeutic strategies and to confine the tumor microenvironment 
to minimize the possibility of metastasis. 
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There is dichotomy in function of CXCR2 in NSCLC.  In the stroma, it acts as an angiogenic 
factor and helps in tumor proliferation, but on the other side by the recruitment of the 
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unpredictable effects depending on the relative balance between these two different 
functions 4. 
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1. Introduction 
Breast cancer is the most common type of malignancy in the world and is also one of the 
major reasons of mortality among women worldwide. It exhibits a vast variety of 
pathological features and clinical signs and said to be a heterogeneous disease (Jemal et al., 
2009). It is also among the most studied cancers, but the biology of it is still not well 
understood (Fang et al., 2011). Genetics, inheritance, aging are major risk factors for breast 
cancer, while hormonal factors, obesity (imitating in diet and exercise), and alcohol use 
presenting more diffident risk. Breast cancer mortality has been found to be decreasing 
gradually since 1990s, after the improvement of breast cancer screening techniques and the 
advancement of treatment approaches (Jatoi and Miller, 2003; and Tabar et al., 2003).  
1.1 Incidence of breast cancer in Pakistan 
In Pakistan, breast cancer has maximum prevalence of all types of cancer, with frequencies 
similar to Western population. It affects mostly young women (45 or above) in Pakistan with 
a high frequency as compared to Caucasian women (Kakarala et al., 2010), often presenting 
in advanced stage (Malik, 2002). The low socio-economic status and reproductive issues 
such as low parity and late first pregnancy may be responsible for higher incidence of breast 
cancer in Pakistan. It is described that patients with lower socio-economic status (SES) had 
larger, more aggressive tumors with worsened survival outcomes (Aziz et al., 2010). The 
mutations of BRCA1 and BRCA2 genes are also considered as responsible factors for the 
greater numbers of breast cancer in Pakistan. As Pakistan has the maximum number of 
consanguineous marriages in the world (Hashmi, 1997), the transfer of these mutations after 
such marriages is supposed to be a vital factor in raising breast cancer cases in Pakistan 
(Shami et al., 1991). The inheritance of recessive genes has been reported to increase the 
breast cancer risk in Pakistan (Liede et al., 2002). But the exact reasons for high incidence of 
breast cancer in Pakistan are still to be detected.  
All these risks put an emphasis on the development of better treatment strategies for breast 
cancer. Early finding of diseased condition, improvements in scientific methodologies and 
quality of care, with sufficient economic guidelines, need to be developed for countries with 
limited resources like Pakistan (Aziz et al., 2008). 
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1. Introduction 
Breast cancer is the most common type of malignancy in the world and is also one of the 
major reasons of mortality among women worldwide. It exhibits a vast variety of 
pathological features and clinical signs and said to be a heterogeneous disease (Jemal et al., 
2009). It is also among the most studied cancers, but the biology of it is still not well 
understood (Fang et al., 2011). Genetics, inheritance, aging are major risk factors for breast 
cancer, while hormonal factors, obesity (imitating in diet and exercise), and alcohol use 
presenting more diffident risk. Breast cancer mortality has been found to be decreasing 
gradually since 1990s, after the improvement of breast cancer screening techniques and the 
advancement of treatment approaches (Jatoi and Miller, 2003; and Tabar et al., 2003).  
1.1 Incidence of breast cancer in Pakistan 
In Pakistan, breast cancer has maximum prevalence of all types of cancer, with frequencies 
similar to Western population. It affects mostly young women (45 or above) in Pakistan with 
a high frequency as compared to Caucasian women (Kakarala et al., 2010), often presenting 
in advanced stage (Malik, 2002). The low socio-economic status and reproductive issues 
such as low parity and late first pregnancy may be responsible for higher incidence of breast 
cancer in Pakistan. It is described that patients with lower socio-economic status (SES) had 
larger, more aggressive tumors with worsened survival outcomes (Aziz et al., 2010). The 
mutations of BRCA1 and BRCA2 genes are also considered as responsible factors for the 
greater numbers of breast cancer in Pakistan. As Pakistan has the maximum number of 
consanguineous marriages in the world (Hashmi, 1997), the transfer of these mutations after 
such marriages is supposed to be a vital factor in raising breast cancer cases in Pakistan 
(Shami et al., 1991). The inheritance of recessive genes has been reported to increase the 
breast cancer risk in Pakistan (Liede et al., 2002). But the exact reasons for high incidence of 
breast cancer in Pakistan are still to be detected.  
All these risks put an emphasis on the development of better treatment strategies for breast 
cancer. Early finding of diseased condition, improvements in scientific methodologies and 
quality of care, with sufficient economic guidelines, need to be developed for countries with 
limited resources like Pakistan (Aziz et al., 2008). 
                                                 





2. Biological explanation of breast cancer 
Breast cancer usually arises after menopause (age: 40+), but it can also arise before 
menopause in very rare cases. The ovarian-pituitary axis synchronizes the normal breast 
physiology during the reproductive cycle. The biological reason for it is that the glandular 
component of the breast gradually degenerates after menopause and the breast is mostly 
substituted by adipose tissue. Any problem in this process causes the development of breast 
cancer, whereas by epithelial cells of the breast ducts, uncontrolled growth and survival 
takes place, and in later stages the characteristics of neo-angiogenesis, invasion and 
metastasis occurs (Heldermon and Ellis, 2006). 
3. Treatment and prevention 
Breast cancer prevention is primarily made by pharmacoprevention using fenretinide and 
tamoxifen. The regular use of screening techniques for early detection of breast cancer is the 
best strategy to decrease death rates (Veronesi and Boyle, 1993). Better treatments include 
targeted chemotherapy, endocrine therapy, radiotherapy and surgery, inhibitors of certain 
proteins and more recently immune therapy (monoclonal antibodies) and miRNA therapy. 
Advancement in life style may also be a good treatment for breast cancer. Breast cancer 
threat may be reduced by physical activities or exercise (Eliassen et al., 2010). 
Many targeted genetic and molecular agents have been developed for efficient treatment of 
breast cancer, by keeping in view certain biomolecular characteristics of breast cancer, such 
as mutations of breast cancer susceptibility gene type 1, 2 (BRCA1/BRCA2) (Chen and 
Parmigiani, 2007), abnormal activation of human epidermal growth factor receptors (EFGR) 
(Wang and greene, 2007), overexpression of human epidermal growth factor receptor-2 
(HER-2) (Ross et al., 2003), and activation of vascular endothelial growth factor (VEGF) 
receptor (Bhinder and Ramaswamy, 2010). It is reported that more than half of the breast 
cancer cases are due to errors in hormone receptor proteins. For this reason, the primary 
concern of today’s research is endocrine therapy. The development of targeting molecular 
agents is also among major goals of current research for efficient treatment of advanced 
breast cancer. 
The major obstacles in treatment of breast cancer are resistance to therapeutic agents 
(Serrano-Olvera et al., 2006). Women with breast cancer treatment and surgery have 
complaints of tension and depression. By using different treatment strategies including 
mastectomy, adjuvant chemotherapy, many women have shown incidence of nervousness 
and depression associated with cancer that puts unpleasant effects on the life status and 
emotional working. 
3.1 Chemotherapy 
Chemotherapy is the most primitive method for treating breast cancer, if employed 
immediately after surgery, termed as adjuvant chemotherapy (AC), and administered before 
surgery, neoadjuvant chemotherapy (NAC) (Alvarado-Cabrero et al., 2009). Chemotherapy 
is recommended for all women with invasive cancer greater than 1 centimeter (Ganz et al., 
2011). Adjuvant chemotherapy is associated with significantly more severe physical 
symptoms, including musculo-skeletal pain, vaginal and weight problems and nausea 
(Ganz et al., 2011). 
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3.1.1 Neoadjuvant chemotherapy 
Neoadjuvant chemotherapy (NAC) has been a common approach for the management and 
treatment of locally advanced breast cancer (LABC). It is applied very effectively for 
treatment of patients with LABC before breast and axillary lymph node resection (Pusztai, 
2008). The NAC is aimed to reduce tumor size subsequently aiding mastectomy and 
radiotherapy (Cleator et al., 2002; and Pusztai, 2008). NAC is better treatment option because 
it averts adverse physiological reactions (Alvarado-Cabrero et al., 2009). 
Patients of LABC had showed complete clinical and pathological response to NAC, while 
those with pure micropapillary carcinoma (PMC) gave incomplete response (Alvarado-
Cabrero et al., 2009). Patient’s therapy effect can be predicted by clinical & pathological 
responses (Jones et al., 2006), and by biomarker levels in the patients, which have better 
prognostic influence in contrast to pathological and clinical response, multi-biomarker levels 
have showed better expressive power for treatment outcome as compared with single 
biomarker level (Nolen et al., 2008).  
Paclitaxel is a chemical agent applied before radiotherapy and surgery. It binds to tubulin 
resulting in cell cycle arrest at M-phase which enhances radiation sensitivity. In a report, 
Patients having 3 cycles of paclitaxel followed by simultaneous radiotherapy before specific 
surgery, showed better results as compared those without paclitaxel (Chakravarthy et al., 
2000). The most common approach for treating LABC in developed countries consists of 
NAC with anthracyclines and taxanes followed by surgery and radiation therapy (Osako et 
al., 2007). HR-positive tumors are less chemosensitive so an anthracyline based NAC is 
developed without hormonal treatment to evaluate estrogen receptor (ER) and progesterone 
receptor (PgR) semi-quantitative expression in patients with HR-positive tumors (Petit et al., 
2010). Preoperative and postoperative marker studies in NAC might facilitate tumor 
analysis and to observe possible change in status respectively (Piper et al., 2004). 
3.2 Endocrine therapy 
An understanding of the mechanism of action, pharmacology and clinical indications for 
various classes of endocrine agent is critical for the management of breast cancer 
(Heldermon and Ellis, 2006). Breast cancer is divided into three major molecular types 
which are diagnosed by routine histopathological tests: (i) hormone receptor-positive 
(ER/PR+), (ii) human epidermal growth factor receptor type 2 enriched (HER2+) and (iii) 
triple negative (ER-, PR-, HER2-) breast cancer (TNBC). HR+ breast cancers comprise about 
60–70% of all the clinically positive breast cancers, while the other two types equally 
accounts for the remaining 30–40% of all breast cancer cases (Slamon et al., 1989). Endocrine 
therapy has been used before surgery but Dittmer et al., (2011) reported adjuvant endocrine 
therapy not so effective for breast tumor treatment because of its side effects (Dittmer et al., 
2011).  
3.2.1 HER2+ breast cancer and targeted therapy 
The HER2 overexpression due to gene amplification or transcriptional deregulation (Slamon 
et al., 1989) presents a poorer prognosis, with development of resistance to many 
chemotherapeutic and hormonal agents, and a rise in tendency of metastasis to brain 





2. Biological explanation of breast cancer 
Breast cancer usually arises after menopause (age: 40+), but it can also arise before 
menopause in very rare cases. The ovarian-pituitary axis synchronizes the normal breast 
physiology during the reproductive cycle. The biological reason for it is that the glandular 
component of the breast gradually degenerates after menopause and the breast is mostly 
substituted by adipose tissue. Any problem in this process causes the development of breast 
cancer, whereas by epithelial cells of the breast ducts, uncontrolled growth and survival 
takes place, and in later stages the characteristics of neo-angiogenesis, invasion and 
metastasis occurs (Heldermon and Ellis, 2006). 
3. Treatment and prevention 
Breast cancer prevention is primarily made by pharmacoprevention using fenretinide and 
tamoxifen. The regular use of screening techniques for early detection of breast cancer is the 
best strategy to decrease death rates (Veronesi and Boyle, 1993). Better treatments include 
targeted chemotherapy, endocrine therapy, radiotherapy and surgery, inhibitors of certain 
proteins and more recently immune therapy (monoclonal antibodies) and miRNA therapy. 
Advancement in life style may also be a good treatment for breast cancer. Breast cancer 
threat may be reduced by physical activities or exercise (Eliassen et al., 2010). 
Many targeted genetic and molecular agents have been developed for efficient treatment of 
breast cancer, by keeping in view certain biomolecular characteristics of breast cancer, such 
as mutations of breast cancer susceptibility gene type 1, 2 (BRCA1/BRCA2) (Chen and 
Parmigiani, 2007), abnormal activation of human epidermal growth factor receptors (EFGR) 
(Wang and greene, 2007), overexpression of human epidermal growth factor receptor-2 
(HER-2) (Ross et al., 2003), and activation of vascular endothelial growth factor (VEGF) 
receptor (Bhinder and Ramaswamy, 2010). It is reported that more than half of the breast 
cancer cases are due to errors in hormone receptor proteins. For this reason, the primary 
concern of today’s research is endocrine therapy. The development of targeting molecular 
agents is also among major goals of current research for efficient treatment of advanced 
breast cancer. 
The major obstacles in treatment of breast cancer are resistance to therapeutic agents 
(Serrano-Olvera et al., 2006). Women with breast cancer treatment and surgery have 
complaints of tension and depression. By using different treatment strategies including 
mastectomy, adjuvant chemotherapy, many women have shown incidence of nervousness 
and depression associated with cancer that puts unpleasant effects on the life status and 
emotional working. 
3.1 Chemotherapy 
Chemotherapy is the most primitive method for treating breast cancer, if employed 
immediately after surgery, termed as adjuvant chemotherapy (AC), and administered before 
surgery, neoadjuvant chemotherapy (NAC) (Alvarado-Cabrero et al., 2009). Chemotherapy 
is recommended for all women with invasive cancer greater than 1 centimeter (Ganz et al., 
2011). Adjuvant chemotherapy is associated with significantly more severe physical 
symptoms, including musculo-skeletal pain, vaginal and weight problems and nausea 
(Ganz et al., 2011). 
 
Treatment of Breast Cancer: New Approaches 
 
87 
3.1.1 Neoadjuvant chemotherapy 
Neoadjuvant chemotherapy (NAC) has been a common approach for the management and 
treatment of locally advanced breast cancer (LABC). It is applied very effectively for 
treatment of patients with LABC before breast and axillary lymph node resection (Pusztai, 
2008). The NAC is aimed to reduce tumor size subsequently aiding mastectomy and 
radiotherapy (Cleator et al., 2002; and Pusztai, 2008). NAC is better treatment option because 
it averts adverse physiological reactions (Alvarado-Cabrero et al., 2009). 
Patients of LABC had showed complete clinical and pathological response to NAC, while 
those with pure micropapillary carcinoma (PMC) gave incomplete response (Alvarado-
Cabrero et al., 2009). Patient’s therapy effect can be predicted by clinical & pathological 
responses (Jones et al., 2006), and by biomarker levels in the patients, which have better 
prognostic influence in contrast to pathological and clinical response, multi-biomarker levels 
have showed better expressive power for treatment outcome as compared with single 
biomarker level (Nolen et al., 2008).  
Paclitaxel is a chemical agent applied before radiotherapy and surgery. It binds to tubulin 
resulting in cell cycle arrest at M-phase which enhances radiation sensitivity. In a report, 
Patients having 3 cycles of paclitaxel followed by simultaneous radiotherapy before specific 
surgery, showed better results as compared those without paclitaxel (Chakravarthy et al., 
2000). The most common approach for treating LABC in developed countries consists of 
NAC with anthracyclines and taxanes followed by surgery and radiation therapy (Osako et 
al., 2007). HR-positive tumors are less chemosensitive so an anthracyline based NAC is 
developed without hormonal treatment to evaluate estrogen receptor (ER) and progesterone 
receptor (PgR) semi-quantitative expression in patients with HR-positive tumors (Petit et al., 
2010). Preoperative and postoperative marker studies in NAC might facilitate tumor 
analysis and to observe possible change in status respectively (Piper et al., 2004). 
3.2 Endocrine therapy 
An understanding of the mechanism of action, pharmacology and clinical indications for 
various classes of endocrine agent is critical for the management of breast cancer 
(Heldermon and Ellis, 2006). Breast cancer is divided into three major molecular types 
which are diagnosed by routine histopathological tests: (i) hormone receptor-positive 
(ER/PR+), (ii) human epidermal growth factor receptor type 2 enriched (HER2+) and (iii) 
triple negative (ER-, PR-, HER2-) breast cancer (TNBC). HR+ breast cancers comprise about 
60–70% of all the clinically positive breast cancers, while the other two types equally 
accounts for the remaining 30–40% of all breast cancer cases (Slamon et al., 1989). Endocrine 
therapy has been used before surgery but Dittmer et al., (2011) reported adjuvant endocrine 
therapy not so effective for breast tumor treatment because of its side effects (Dittmer et al., 
2011).  
3.2.1 HER2+ breast cancer and targeted therapy 
The HER2 overexpression due to gene amplification or transcriptional deregulation (Slamon 
et al., 1989) presents a poorer prognosis, with development of resistance to many 
chemotherapeutic and hormonal agents, and a rise in tendency of metastasis to brain 





3.2.2 Monoclonal antibodies for endocrine therapy 
The basic purpose of current therapeutic policies is to make overexpressed HER2 silent 
with certain targeted complexes e.g., trastuzumab, a monoclonal antibody prepared for 
humans against HER2 protein, reported to be a well accepted therapy for women with 
MBC (Vogel et al., 2002). This antibody specifically hinders the HER2-mediated activation 
of intracellular kinases and other molecules (Valabrega et al., 2007). The combination of 
chemotherapy and trastuzumab extends the life of patient in adjuvant and metastatic 
patterns, but most women with HER2+ metastatic tumor become resistant to trastuzumab; 
about 15–25% of women detected with early HER2+ disease have trastuzumab-resistant 
tumors (Bedard et al., 2009).  
The combinations of anti-HER2 agents should close to abolish acquired drug resistance, 
shorten the period of therapy, and potentially dole out with the need of coexisting 
chemotherapy, because the anti-HER2 therapies including drugs trastuzumab and lapatinib, 
targeted against the HER2 signaling network has gradually changed the natural history  
of early and metastatic HER2-overexpressing breast cancer (Abramason and Artega,  
2011). 
3.2.3 HR+ breast cancer and targeted therapy 
Estrogen is a well-characterized growth factor in about 60–70% of breast cancer patients 
(Clemons and Goss, 2001). The malignant epithelial cells depend on reproductive hormones, 
specifically estrogen in ER+ tumors (Heldermon and Ellis, 2006). The initial endocrine 
therapy of breast cancer was removal of the ovaries (oophorectomy) (Taylor et al., 1998). 
Many thriving remedies have been formulated to decrease or eradicate circulating estrogen 
or to obstruct its communication with genomic target objects. The specific ER antagonist 
tamoxifen is recommended as adjuvant endocrine therapy for the hormone receptor positive 
early breast cancer (Sehdev et al., 2009).  Endocrine therapies for ER+ patients include three 
types of agents that (i) directly target ER through molecules that bind ER and change ER 
function; (ii) estrogen deprivation through aromatase inhibition or ovarian suppression; and 
(iii) sex steroid therapies, including estrogen, progestins and androgens. 
3.2.4 Selective Estrogen Receptor Modulators (SERM) 
The rise of estrogen level in blood proposed the use of a therapeutic modulator to oestrogen, 
a selective oestrogen receptor modulator, or SERM (Jordan, 1999). The evidences from 
breast cancer treatment trials presented the ability of the first SERM, tamoxifen, to avoid 
tumors in the contralateral breast of women receiving adjuvant therapy (Ragaz and 
Coldman, 1998). Tamoxifen considerably lessens the rate of treatment failure in breast 
cancer patients, with lesser frequency of clinically obvious toxic effects. For tamoxifen, 
response rates range from 16 to 56%, and an improved toxicity profile than alternative 
therapies, for example large dosage of estrogen or adrenalectomy results in quick 
acceptance of tamoxifen as a selective cure for advanced disease (Muss et al., 1994). The 
combination of ovarian suppression and tamoxifen is referred to as the first line therapy for 
HR+ advanced breast cancer in pre-menopausal women. Some examples of SERM comprise 
raloxifene and toremifine (Holli et al., 2000; and Martino et al., 2004).  
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3.2.5 Tyrosine kinase inhibitors 
Lapatinib is an oral, selective, reversible small-molecule dual tyrosine kinase inhibitor of both 
the ErbB1 and ErbB2 signaling pathway that works by inhibiting growth and guiding to cell 
arrest and apoptosis. It is presented to be effective against HER-2+, LABC and metastatic breast 
cancer (MBC). The primary activity of lapatinib in breast cancer patients is mediated through 
HER-2 inhibition. In addition, lapatinib treatment inhibits the growth of ErbB2-overexpressing 
human breast cancer cells that showed resistance to trastuzumab. Clinically related antitumor 
activity has not been reported when lapatinib is used in the mixed population of LABC patients 
with distinct HER-2 negative or HER-2 untested tumors (Leo et al., 2008). Patients with HER-2 
negative or HER-2 untested MBC had not showed any advantage from lapatinib therapy. 
However, the first-line therapy with paclitaxel and lapatinib in combination expressed 
improved clinical outcomes in HER-2+ patients. Future assessment of the effectiveness and 
safety of this combination is constant in early and metastatic HER-2+ breast cancer patients. A 
combined targeted approach with letrozole and lapatinib has appreciably improved 
progression free survival in patients with MBC that coexpresses HR and HER2. 
3.2.6 Triple-negative breast cancer treatment 
CCN1, also known as Cyr61 (cysteine-rich 61), is a proangiogenic factor, increased CCN1 
expression is associated with the development of tumors (O'Kelly et al., 2008), e.g., in about 
30% of invasive breast carcinomas, and particularly in triple-negative breast carcinomas 
(TNBC). TNBCs patients had been treated with bisphosphonate in combination to 
chemotherapy. Zoledronic acid (ZOL) is a bisphosphonate having direct antitumor activity 
in breast tumor cells by preventing independent growth, branching and morphogenesis by 
targeting CCN1 overexpressing cells through a negative regulation of CCN1 by FOXO3a; it 
is a new therapeutic approach for TNBC (Espinoza et al., 2011). 
3.3 Anti-angiogenic therapies 
Angiogenesis is the mandatory step in tumor development, so anti-angiogenic agents can be 
developed for the better management and prevention of breast tumor. The monoclonal 
antibody to platelet/endothelial cell adhesion molecule (PECAM) has proved to be a 
sensitive and specific marker for endothelial cells; these antibodies might reduce the tumor 
size or hinder the development of metastatic tumors (Horak et al., 1992). 
3.3.1 Viral vector therapy 
Expression of VEGF in several types of tumors is amplified, subsequently correlated with 
weak prognosis of several tumors. Im et al (2001) used transfection method to create a 
replication-deficient adenoviral vector containing antisense VEGF cDNA (Ad5CMV-
αVEGF) to down-regulate VEGF expression. This therapeutic strategy notably repressed the 
growth of developed breast tumors (Im et al., 2001). These viral vectors may be used in 
future for targeting the tumor vasculature in breast cancer therapy. 
3.4 Surgery 
Mastectomy is total removal of one or both breasts; it is frequently used in treatment of 
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effective therapeutic approach for breast cancers with BRCA1 and BRCA2 mutations 
(Meijers-Heijboer et al., 2001). Lumpectomy or breast conserving surgery (i.e., surgical 
removal of discrete tumor from breast) may be used alone or in combination with 
subsequent radiotherapy, later is reported to be more appropriate therapy for invasive 
breast cancer; because the risk of ipsilateral recurrence of breast cancer is very low in 
lumpectomy with irradiation as compared with mastectomy and lumpectomy alone (Fisher 
et al., 2002). For hormone receptor positive breast cancer, initial treatment option was 
surgical removal of ovaries, oophorectomy (Taylor et al., 1998). 
3.5 Radiotherapy 
Radiotherapy is applied after surgery, i.e., adjuvant radiotherapy. Cardiovascular disease 
continues to be chief problem of radiotherapy in breast cancer patients, but a little is known 
about it yet; It raises the enduring threat for cardiovascular mortality, predominantly in 
women treated for left-sided breast cancer; the mortality rate due to cardiac disease may boost 
to double in left-sided breast cancer survivors as compared to right-sided breast cancer 
patients (Foody, 2011). In women (aged 70+) with tumors larger than 5 cm, minor local 
regional recurrence (LRR)  was observed through radiotherapy following mastectomy than 
those lacking radiotherapy (Truong et al., 2005); Post-mastectomy radiotherapy (PMRT) might 
be helpful in the managing breast cancer with high-risk features (Lee et al., 2005). Adjuvant 
radiotherapy is proved to be a breast conserving therapy (BCT) in younger women, it is not 
frequently recommended for patients with older age (Nagel et al., 2002). Postoperative 
radiotherapy is normally in use for treating patients with positive surgical margins following 
mastectomy but a little data is present to sustain this approach (Truong et al., 2004). 
3.6 miRNA therapy 
Each tumor type seems to have a unique miRNA marker, and such markers are being 
oppressed to recognize the tissue of origin of metastatic tumors and to distinguish between 
different cancer subtypes (Lu et al., 2005). Furthermore, miRNA expression markers are 
linked to numerous clinicopathological features for instance tumor stage, receptor status 
and patient survival. Eventually, it is likely to make profiles that characterize a probable link 
between circulating miRNAs, disease status, basic subtype and HER2+ status, therapeutic 
response and metastatic risk. As miRNA expression is vanished during MBC, the renovation 
of these miRNAs’ expression may suppress MBC; for example, miR-126 renovation reported 
to decrease in general tumor growth and propagation, and miR-335 presented to inhibit 
metastatic cell invasion (Tavazoie et al., 2008). 
3.7 Male breast cancer and treatment 
Breast cancer is recently described to exist in males too. Tamoxifen, aromatase inhibitors and 
GnRH analogues targeting on HER2-directed therapies, PARP inhibitors, and angiogenesis 
inhibitors are reported endocrine therapeutic strategies for treating male breast cancer 
(Onami et al., 2010). 
4. Conclusion 
Breast cancer is a heterogeneous disease and has become the most common cancer in 
women throughout the world. Known risk factors include age, dietary features, 
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reproductive hormonal imbalance, genetic predispositions, alcoholism, and breast adipose 
tissue density. Breast cancer is major cause of mortality of women worldwide. Keeping in 
view the above discussion, here is a need of developing better therapeutic plans for 
hampering breast cancer risks and reducing mortality due to breast cancer. Research 
investigating cultural, environmental, and genetic issues of breast cancer should be taken 
into consideration for development of better treatment plans and to present additional 
details for the clinical and pathological features. The molecular, endocrine and genetic 
means should be the major goals of today’s efforts for treatment of breast cancer. 
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effective therapeutic approach for breast cancers with BRCA1 and BRCA2 mutations 
(Meijers-Heijboer et al., 2001). Lumpectomy or breast conserving surgery (i.e., surgical 
removal of discrete tumor from breast) may be used alone or in combination with 
subsequent radiotherapy, later is reported to be more appropriate therapy for invasive 
breast cancer; because the risk of ipsilateral recurrence of breast cancer is very low in 
lumpectomy with irradiation as compared with mastectomy and lumpectomy alone (Fisher 
et al., 2002). For hormone receptor positive breast cancer, initial treatment option was 
surgical removal of ovaries, oophorectomy (Taylor et al., 1998). 
3.5 Radiotherapy 
Radiotherapy is applied after surgery, i.e., adjuvant radiotherapy. Cardiovascular disease 
continues to be chief problem of radiotherapy in breast cancer patients, but a little is known 
about it yet; It raises the enduring threat for cardiovascular mortality, predominantly in 
women treated for left-sided breast cancer; the mortality rate due to cardiac disease may boost 
to double in left-sided breast cancer survivors as compared to right-sided breast cancer 
patients (Foody, 2011). In women (aged 70+) with tumors larger than 5 cm, minor local 
regional recurrence (LRR)  was observed through radiotherapy following mastectomy than 
those lacking radiotherapy (Truong et al., 2005); Post-mastectomy radiotherapy (PMRT) might 
be helpful in the managing breast cancer with high-risk features (Lee et al., 2005). Adjuvant 
radiotherapy is proved to be a breast conserving therapy (BCT) in younger women, it is not 
frequently recommended for patients with older age (Nagel et al., 2002). Postoperative 
radiotherapy is normally in use for treating patients with positive surgical margins following 
mastectomy but a little data is present to sustain this approach (Truong et al., 2004). 
3.6 miRNA therapy 
Each tumor type seems to have a unique miRNA marker, and such markers are being 
oppressed to recognize the tissue of origin of metastatic tumors and to distinguish between 
different cancer subtypes (Lu et al., 2005). Furthermore, miRNA expression markers are 
linked to numerous clinicopathological features for instance tumor stage, receptor status 
and patient survival. Eventually, it is likely to make profiles that characterize a probable link 
between circulating miRNAs, disease status, basic subtype and HER2+ status, therapeutic 
response and metastatic risk. As miRNA expression is vanished during MBC, the renovation 
of these miRNAs’ expression may suppress MBC; for example, miR-126 renovation reported 
to decrease in general tumor growth and propagation, and miR-335 presented to inhibit 
metastatic cell invasion (Tavazoie et al., 2008). 
3.7 Male breast cancer and treatment 
Breast cancer is recently described to exist in males too. Tamoxifen, aromatase inhibitors and 
GnRH analogues targeting on HER2-directed therapies, PARP inhibitors, and angiogenesis 
inhibitors are reported endocrine therapeutic strategies for treating male breast cancer 
(Onami et al., 2010). 
4. Conclusion 
Breast cancer is a heterogeneous disease and has become the most common cancer in 
women throughout the world. Known risk factors include age, dietary features, 
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reproductive hormonal imbalance, genetic predispositions, alcoholism, and breast adipose 
tissue density. Breast cancer is major cause of mortality of women worldwide. Keeping in 
view the above discussion, here is a need of developing better therapeutic plans for 
hampering breast cancer risks and reducing mortality due to breast cancer. Research 
investigating cultural, environmental, and genetic issues of breast cancer should be taken 
into consideration for development of better treatment plans and to present additional 
details for the clinical and pathological features. The molecular, endocrine and genetic 
means should be the major goals of today’s efforts for treatment of breast cancer. 
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